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Metabolic and energetic requirements of cancer cells are very different 
from normal cells. Tumor cells use predominantly glycolysis for ATP 
production, unlike in normal cells, where the main source of ATP is oxidative 
phosphorylation in the mitochondria. This is termed Warburg effect and such a 
metabolic reprogramming is a hallmark of cancer that is essential for cancer 
cells to maintain aggressive growth. Frataxin (FXN) is a mitochondrial protein 
that reportedly influences both glucose and iron metabolism in the cell. FXN 
interacts functionally with the electron transport chain proteins in the 
mitochondria to influence oxidative phosphorylation, and FXN deficiency 
resulted in defective mitochondrial ATP production. Studies have shown that 
FXN knockout increases tumorigenicity in cancer cell lines and induces tumor 
formation in animal model. Over-expression of FXN has been demonstrated to 
possess anti-cancer effects. However, the molecular mechanisms of FXN as a 
potential tumor suppressor are largely unknown. This thesis aims to elucidate 
the role of FXN over-expression in tumor cells. Proteome and metabolic 
changes induced by stable over-expression of FXN in colorectal cancer cell 
line HCT116 (OF) were investigated in this study. Using iTRAQ analysis, 
abundance of 276 proteins was found to be significantly different. Pathway 
analysis of these dysregulated targets recapitulated perturbed (i) mitochondrial 
ATP production, (ii) cellular reactive oxygen species (ROS) status and (iii) 
cell cycle and proliferation. Functional assays were performed to validate the 
effect of FXN over-expression. OF cells were demonstrated to possess 
characteristics of increased oxidative phosphorylation, better resistance 
towards endogenous ROS insult and a decreased intracellular ROS. Our cell 
 ix 
 
cycle analysis suggested that reduced cell proliferation in OF cells might be 
due to a delayed transition of G1 to S phase. Further examination of perturbed 
targets points to alteration of hypoxia state of the cells. Destabilization of HIF-
1α in OF cells was demonstrated to be associated with metabolic changes and 
anti-cancer effect observed. Among them, a downstream target of HIF-1α, 
EMMPRIN, which is associated with tumor progression and malignancy, has a 
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1.1 Cancer  
Cancer is the most common cause of death in developed countries and the 
second biggest reason for mortality in developing countries [1]. Presenting as a 
complex syndrome that could affect any part of the body, cancer is best 
characterized by rapid and uncontrolled growth of abnormal cells with the capacity 
to spread to distant sites as metastases. Cancer pathogenesis generally begins with 
‘in situ’ growth, followed by invasion, extravasation and eventually metastasis. In 
Singapore, around 10,000 cases of cancer is reported yearly with an increasing trend. 
In Singapore, colorectal cancer is the most common cancer in Singaporean males 
and second most common cancer amongst Singaporean females (Source: National 
Cancer Centre, Singapore). 
1.1.1 Hallmarks of cancer 
Characteristics of cancer may be summarized into six hallmarks (Fig 1-1). 
These include sustaining proliferative signaling, evading growth suppressors, 
activating invasion and metastasis, enabling replicative immortality, inducing 
angiogenesis and resisting cell death [2]. These capabilities are often progressively 






Figure 1-1: Hallmarks of cancer. Six original hallmarks of cancer, describing the 
biological capabilities attained during tumorigenesis. These hallmarks are presumably the 
result of underlying genome instability of cancer cells. (Adopted from Hanahan D. and 
Weinberg R.A. [3] with permission). 
 
Sustaining proliferative signaling refers to the ability to sustain proliferation 
without the need for external growth-promoting signals. Through mutations, cancer 
cells may acquire the capability to sustain growth signaling in a few ways. For 
example, cancer cells may be capable of autocrine secretion or may acquire an 
activating mutation downstream of signaling molecules such as the Rat sarcoma 
(Ras) oncogene or even transcription factors such as Myc that drive cellular 
proliferation [4]. At the same time, anti-proliferative mechanisms must be 
suppressed during tumorigenesis. For example,  transforming growth factor beta 
(TGFβ) that activates tumor suppressor retinoblastoma (pRB), to inhibit cell cycle 
progression may be triggered [5]. The loss of functional pRB is common in many 
tumors and a driving factor in tumor progression [6].  
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The ability of tumors to grow and increase in mass is not only the result of 
uncontrolled proliferation but also with evasion of programmed cell death, apoptosis. 
Apoptosis is an innate cellular suicide mechanism often triggered to remove 
undesired cells from the body. For aberrant cancer cells to survive, apoptosis has to 
be circumvented. Cancer cells resist cell death through regulating both anti-
apoptotic and pro-apoptotic signals [7].  
Even after successfully escaping from apoptosis, cancer cells still may not 
divide forever as there exists a built-in replicative limit. Telomeres are DNA regions 
that cap the end of chromosomes to prevent lethal chromosomal end-to-end joining. 
Telomeres erode with each cell division, placing a limit on the number of times a 
cell can divide.  In cancerous states, enabling replicative immortality is most 
commonly achieved by continuous addition of telomeres by the enzyme telomerase 
[8].  
After overcoming restraints to growth signaling, apoptosis and replicative 
mortality, tumor cells expand in numbers and accumulate in mass. At this stage, 
nutrients would become inevitably scarce and the proliferating tumor mass requires 
new sources of materials for further growth. Tumor cells thus promote the formation 
of nascent blood vessels and capillaries by turning on the angiogenic switch and 
hijacking the normal angiogenic machinery [9]. With vasculation at the primary 
tumor site, the tumor mass gains nourishment for further expansion and more 
importantly gains access to the circulation for dissemination.  
Metastatic spread takes two major phases: intravasation of tumor cells into 
blood vessel, and extravasation and adaption to microenvironment at distant site.  
The activation of invasive and metastatic phenotype is triggered by many classes of 
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proteins collectively involved in epithelial-to-mesenchymal transition, cell motility, 
adhesion, and extracellular protease activity [10].   
 
Figure 1-2: Emerging Hallmarks and enabling characteristics of cancer. New findings 
suggest that deregulation of cellular energetics and avoiding immune destruction are 
additional hallmarks of cancer. In addition, genome instability and mutation, and tumor-
promoting inflammation characteristics further support cancer progression. (Adopted from 
Hanahan D. and Weinberg R.A. [3] with permission). 
 
In recent years, new hallmarks of cancer have emerged with more extensive 
study. Two enabling characteristics (Fig 1-2) further aid cancer cells in the 
acquisition of the six original cancer hallmarks described previously. Genomic 
instability is the basis for genetic changes that endow cancer cells with these 
hallmarks. Cancer progression is a multistep acquisition of aberrant advantages over 
normal cells, which may be understood as the activation of proto-oncogene with the 
loss of functional tumor suppressors. In this respect, accumulation of mutation due 
to genomic instability is the main driving force.  
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The second enabling characteristic involves inflammatory response during 
early malignancy that promotes tumorigenesis. It is now a consensus that immune 
cells can infiltrate almost all types of neoplastic lesions and at various stages of 
cancer progression [11]. Initially these immune responses were thought to be the 
body’s effort in eliminating tumors. Increasing evidence recently however show that 
cancer cells may instead coax immune cells into supplying bioactive molecules to 
the tumor microenvironment, to contribute to both tumor initiation and progression 
[12].  
Considering the dual roles of inflammation, immune responses constitute a 
key defence mechanism in tumor eradication. Since avoiding immune destruction is 
one of the emerging hallmarks of cancer pathogenesis, cancer cells evolve strategies 
to evade detection, attack and elimination by immune cells. Some of these 
mechanisms involve secretion of immunosuppressive factors [13] or the recruitment 
of regulatory T-cells [14] to further suppress host immune responses.  
The last hallmark of cancer is deregulating cellular energetics. These involve 
reprogramming of the general energy metabolism to support rapid proliferation. This 
emerging hallmark would be further discussed detail in subsequent sections with 
incorporation of experimental data. Collectively, these ten hallmarks of cancer serve 
as a framework for investigating the complexity of cancer biology. 
1.1.2 The Warburg effect 
All cells need energy in the form of adenosine-5-triphosphate (ATP) to 
maintain essential biological processes such as DNA synthesis and repair, protein 
turnover and maintenance of membranes. In the presence of oxygen, glucose is 
metabolized to pyruvate via glycolysis with the generation of two molecules of ATP. 
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The pyruvate then enters the mitochondria where it undergoes further oxidation in 
the citric acid cycle also known as the tricarboxylic acid (TCA) cycle.  
The TCA cycle also generates reducing equivalents in the form of 
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide 
(FADH2). Electrons from NADH and FADH2 are transferred to the Electron 
Transport Chain (ETC) in the inner mitochondrial membrane, and through a series 
of redox reactions, reach the final electron acceptor oxygen. Through the ETC, 
oxidative phosphorylation (OXPHOS) generates another 34 to 36 molecules of ATP 
per molecule of glucose, in addition to 2 ATP generated from glycolytic pathways. 
In the absence of oxygen, however, the ETC cannot function, and cells rely solely 
on glycolytic ATP production to survive. 
In the 1920s, German biochemist Otto Warburg measured the amount of 
glycolytic and oxidative ATP production in normal kidney, liver and cancerous 
ascites tissues. It was discovered that even in oxygenated conditions, ascites cancer 
cells had almost 50% more glycolytic ATP production compared to the normal 
tissues [15]. Cancer cells actively metabolize glucose to produce excessive lactate 
even though oxygen is still consumed by the mitochondrial ETC. Warburg termed 
this phenomenon aerobic glycolysis and proposed that deficit in mitochondrial 
function may be the factor driving tumorigenesis, and that these tumor cells adapt by 
increasing glucose uptake for glycolytic energy production independent of the 
mitochondria. 
The Warburg effect thus summarises drastic modifications in metabolism 
and cellular energetics, that agree with the emerging hallmark of metabolic shifts in 
cancer [3].  
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1.1.3 Cancer cell metabolism 
As described above, cancer cells undergo uncontrolled proliferation to 
rapidly accumulate tumor mass. To fuel this aggressive proliferation and to sustain 
growth when nutrients become limited, it is paradoxical that cancer cells increase 
anaerobic ATP production even though aerobic ATP production is more energy 
efficient per glucose molecule. 
Warburg initially believed cancer cells have a deficit in mitochondrial ATP 
production [16]. However, subsequent evidence showed that not all cancer cells had 
defective OXPHOS [17, 18], and that the occurrence of aerobic glycolysis was not 
only limited to cancers but also observed in normal cells undergoing rapid 
proliferation [19, 20]. Thus the shift to aerobic glycolysis is independent of 
mitochondrial function. 
Although glycolysis is inefficient in producing ATP per molecule of glucose 
compared to OXPHOS [21], glycolysis has a higher turnover rate in ATP generation 
[22].  Therefore, given a continual supply of glucose, like having access to rich 
vasculature, high glycolytic rate may better meet the needs of growth and cell 
division [23]. Several pieces of evidence show that tumour cells indeed have higher 
glucose uptake [24, 25].  
Moreover, cell division requires additional synthesis of cellular components, 
nucleic acids, proteins and lipids. Glucose catabolism in aerobic glycolysis also 
provides the precursors needed in these biosynthetic pathways [26, 27]. The 
glycolytic pathway is linked to the pentose phosphate shunt, which is the main 
source of nicotinamide adenine dinucleotide phosphate (NADPH) and ribose sugar 
for nucleic acid synthesis. TCA cycle intermediates also serve as precursors in 
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amino acid, lipids and nucleic acid biosynthesis [27]. Predominant use of glycolysis 
even in the presence of oxygen thus offers a tremendous advantage in the rate of 
energy production as well as the generation of biosynthetic precursors (Fig 1-3). 
 
Figure 1-3: Biosynthetic precursors derived from metabolic pathways. This schematic 
shows how glycolysis, pentose phosphate pathway, OXPHOS and TCA cycle feed into the 
biosynthesis of NADPH, amino acid, lipids and nucleic acids. Main metabolic pathways are 
labeled in blue, cellular constituents essential for cell division are in purple. Glucose and 
glutamine uptake are increased in proliferating cells and excess lactate excreted. Key 
proteins involved are boxed in blue. Modified from Vander et. al and, Lunt and Vander [26, 































































1.1.4  Mechanisms involved in altered cancer metabolism 
The tumor microenvironment was believed to be the dominant driving force 
in metabolic transformation. During tumorigenesis, lack of blood supply due to poor 
vasculature and the distance of the tumor mass from the nearest blood vessels [28] 
often results in a hypoxic tumor microenvironment [29]. The central molecule that 
responds to hypoxic stress is the hypoxia-inducible factor 1 (HIF-1) [30, 31]. Being 
a master regulator of oxygen homeostasis and metabolism, HIF-1α targets genes 
associated with angiogenesis, glycolysis, cell proliferation and metastasis, and 
permits the survival of tumor cells under hypoxic conditions [32]. 
1.1.5 HIF-1α modulates cancer cell metabolism 
HIF-1 activation promotes glucose uptake by increasing the expression of 
glucose transporter 1 (GLUT1) [33]. Many glycolytic enzymes are also regulated by 
HIF-1, such as phosphofructokinase, fructose-2,6-biphosphatase, aldolase, 
phosphoglycerate kinase and pyruvate kinase [34, 35]. On top of these, HIF-1 also 
regulates the processes of pyruvate conversion into lactate and lactate removal from 
tumor cells [36, 37]. In hypoxic conditions, HIF-1 further regulates mitochondrial 
activity by reducing pyruvate dehydrogenase levels, thereby limiting the use of 
pyruvate in the mitochondria [38, 39]. Since HIF-1 as a transcription factor directly 
regulates the expression of many enzymes causing the shift from OXPHOS to 
aerobic glycolysis, it is an attractive target for potential inhibition of the Warburg 
effect in cancer. 
Moreover, the potential role of HIF-1 in cancer metabolism is further 
strengthened with reports of its activation by oncogenes and loss of tumour 
suppressors [40]. During normoxia, Ras/Raf/MAPK and PI3K/AKT pathways 
activate HIF-1. Loss of tumor suppressor PTEN also reportedly increases HIF-1 
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levels and cause up-regulation of its targets [41]. TCA metabolites such as succinate 
and fumarate in tumor cells can also regulate HIF-1 levels [42].  
Although Warburg effect in cancer cells may be attributed to HIF-1 
activation and transcriptional activity, other factors may also contribute to metabolic 
re-programming. For instance, p53 can regulate glucose metabolism through 
miRNA suppression of glycolytic enzymes [43], or via direct modulation of 
fructose-2,6-bisphosphate and cytochrome c oxidase 2 [44, 45]. Myc oncogene can 
also regulate an array of glycolytic enzymes such as lactate dehydrogenase, 
hexokinase and pyruvate dehydrogenase kinase [46, 47].  Therefore, the control of 
precise changes in aerobic glycolysis in cancer is likely a concerted effect of HIF-1 
with other key oncogenic modulators in the cell.  
1.1.6 Potential therapy targeting cancer metabolism 
Elevated glucose uptake in tumors has been exploited with the use of 2-[18F]-
fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) to detect 
cancerous tissue in humans [48, 49]. FDG is a labeled analogue of glucose, which is 
taken in and metabolized rapidly by tumors. Phosphorylation of FDG by hexokinase 
traps it in the cell due to charge on the phosphate group, allowing it to be detected in 
cancer cells. This imaging technique has been very useful in diagnosis, staging and 
prognosis of cancer. 
Among numerous glycolytic enzymes, hexokinase is one of the key targets 
with two drugs reaching clinical trials. Hexokinase phosphorylation of glucose to 
glucose-6-phosphate is the first limiting step in glycolysis. Since glucose-6-
phosphate also serves as an immediate for pentose phosphate pathway, inhibition of 
hexokinase likely has a profound effect on both glycolysis and the pentose 
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phosphate shunt. A non-metabolizable glucose analogue, 2-deoxyglucose, is 
phosphorylated by hexokinase, but accumulates to inhibit hexokinase via feedback 
mechanism. This inhibits glycolysis and eventually leads to cell death due to 
depletion of ATP, especially in cancer cells with defective OXPHOS [50]. An in 
vivo study showed that 2-deoxyglucose enhances anti-tumor effect of paclitaxel and 
adriamycin in xenograft models [51].  Based on these findings, 2-deoxyglucose had 
entered clinical trials for cancer treatment in combination with other drugs.  
Lonidamine is another drug that also targets hexokinase 2 [52] to deplete 
cellular ATP in a dose dependent manner [53]. Lonidamine can enhance the killing 
effect of several anticancer drugs in combination treatment [54] and has begun 
clinical trials for treatment of early stage prostate cancer [55]. 
 Given the importance of HIF-1α in regulating aerobic glycolysis in tumors, 
HIF-1α is another potential candidate in cancer therapy. Based on the mechanism of 
HIF-1, drugs have been developed to target transcription of HIF-1α mRNA, protein 
translation and degradation, or DNA binding and transcriptional activity [56].  
Topotecan is an FDA approved drug able to inhibit the translation of HIF-1α. 
Treatment using topotecan in mouse glioma model inhibited angiogenesis and tumor 
growth through reducing HIF-1α protein level [57]. Topotecan is in clinical trials in 
various cancers and its efficacy in different drug combinations is also being 
evaluated. A recent phase II study on the use of oral topotecan with bevacizumab 
(Avastin), an angiogenesis inhibitor, in small-cell lung cancer showed promising 
results [58].   
These drugs have shown potential in anticancer treatment but there are still 
concerns that need to be addressed, in particular, the specificity and associated 
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toxicity require further investigation. Thus more in-depth understanding of the 
cellular machinery is necessary and would be an important goal in the study of 
cancer metabolism.  
1.2 A model to study alteration of cancer metabolism 
The development of novel therapeutic strategies targeting cancer metabolism 
would require comprehensive understanding of the machineries involved. The use of 
a model can be beneficial by reducing the complexity of the problem. From the 
current literature, Frataxin (FXN) is a possible candidate given its association with 
the Warburg effect, its anti-tumor effect and proposed functions in the modulation of 
energy metabolism [59].  
1.2.1 Frataxin and Friedreich’s ataxia 
Friedreich’s ataxia (FRDA) is an autosomal hereditary ataxia caused by 
reduced expression of frataxin (FXN). FRDA has an early onset with the mean age 
of 25 and on average, patients with FRDA die by the age of 36.6, predominantly 
from cardiac failure [60]. The lack of FXN causes a wide range of metabolic 
disturbances including, but not restricted to, oxidative stress, iron metabolism and 
deficit in iron sulphur and heme synthesis. The effect of FXN deficiency is most 
severely presented in neurons and heart cells. Symptoms of FRDA include 
neurodegeneration, lost of reflexes in the limbs, sensory neuropathy, skeletal 
deformities and cardiomyopathy [61].  
1.2.2 Structure of the human Frataxin 
FXN is a nuclear-encoded mitochondrial protein highly conserved from 
gram negative bacteria to eukaryotes [62]. FXN gene likely originated from 
proteobacteria which was transferred to the eukaryotic genome after endosymbiosis 
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[63]. The nuclear magnetic resonance (NMR) [64] and crystal structures of FXN [65] 
were both solved in 2000. The FXN structure (Fig 1-4) consists of a large, twisted 
six-stranded antiparallel β-sheet (orange) flanked by N- and C-terminal α-helices 
(pink). The antiparallel β-sheets are mostly neutral and may be involved in protein-
protein interaction, while in contrast, the α1 helix and β1 sheet are negatively 
charged and are believed to interact with iron [66].  
 
Figure 1-4: NMR and crystal structure of human FXN.  A) Solution structure of human 
FXN. PDB ID: 1LY7[64]. B) Crystal structure of human FXN. PDB ID:1EKG [65]. Both 
structures are similar, showing large, twisted six-stranded antiparallel β-sheets in orange 
flanked by N- and C-terminal α-helices in pink. 
 
1.2.3 Frataxin and its implication in metabolism 
FXN was reportedly involved in the synthesis of iron sulphur clusters (ISC) 
[67]. ISCs are prosthetic groups required by many enzymes, including those that are 
involved in signaling, DNA repair, and various metabolic pathways. For example, 
proteins in the complexes I, II and III of the ETC, aconitase and ferredoxin [68] all 
required ISC for normal function. It has been observed that deficiency in FXN leads 






eukaryotic cells [67, 69-71]. These provide evidence that FXN is crucial for ISC 
biosynthesis and could probably also indirectly affect ETC function via its 
regulation of ISC synthesis. It was also proposed that FXN may regulate OXPHOS 
in the mitochondria by interacting functionally with the ETC proteins [72]. 
Clinical validation in patients suffering from FRDA showed defective 
mitochondrial ATP production [73]. Conversely, FXN over-expression increased 
mitochondrial membrane potential in cell line models, accompanied by increased 
OXPHOS [74].  
1.2.4 Association of Frataxin with cancer 
A few cases involving clinical onset of cancer in FRDA individuals is 
summarized in Table 1-1. Two cases reported in 1996 and 2001 involved FRDA 
siblings who developed similar cancers and highlighted possible mechanistic 
correlation between cancer and FXN deficiency. In addition, a recent study reported 
that FXN is associated with DNA repair mechanisms [75] and may be the reason 
behind hypersensitivity to mutagens observed in cells isolated from FRDA patients 
[76, 77]. However, these cases of cancer amongst FRDA patients are uncommon 








Table 1-1: Reported cancer incidents in Friedreich’s ataxia cases. 
No Cancer type Patient(s) Year 
reported
References 
1 Primary small bowel 
ganglionneuroblastoma 
Female, 26 1986 Barr et. al [78] 
2 Gastric carcinoma† Female, 34 
Male, 34 
1996 Ackroyd et. al [79] 
3 Lymphoblastic lymphoma Male, 16 1999 De Pas et. al [80] 
4 Uterine Leiomyoma Female, 39 2011 Misiakos et. al [81] 
5 Breast carcinoma† Female, 39 
Female, 42 
2001 Kidd et. al [82] 
6 Osteogenic sarcoma Female, 19 2012 Deutsch et. al [83] 
† These cases reported siblings developing the same type of cancer. 
The association between FXN and Warburg effect in caner has been 
demonstrated in several in vitro studies. In hepatic FXN knockout mice, hepatocytes 
had disrupted mitochondrial function that caused defective OXPHOS. This was 
accompanied by high oxidative stress which stimulated hepatocyte proliferation. 
These hepatic FXN knockout mice also had significantly higher occurrence of 
multiple liver tumors [84]. Conversely, over-expression of FXN in murine fibroblast 
inhibited malignant transformation and tumor formation in nude mouse [85]. Over-
expression of FXN in colorectal cancer cells was shown to induce OXPHOS, inhibit 
tumor growth and reduce tumor size in mouse xenograft [59]. 
However in another study, FXN level was reported to be elevated in human 
colon tumor tissues [86]. The authors also showed that FXN protein level in cancer 
cell lines may be induced during hypoxia. FXN was additionally associated with 
S15 phosphorylation of p53 during hypoxia. Activation of p53 first promotes cell 
survival, but eventually leads to cell death if left to persist. FXN was thus proposed 
as a tumor suppressor since it affects the adaption of tumor cell to hypoxia by 
modulating p53 activation.  
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Given the possible roles of FXN as discussed so far, FXN is a good 
candidate as a model to further understand the relationship between energy 
metabolism and cancer progression.  
1.3 Omics-based approaches for study of cancer biology 
An “omics”-based study refers to a large scale study of molecules relevant to 
biological systems in cells, tissues or organisms  [87]. Depending on the nature of 
the molecules studied, genomics, proteomics, transcriptomics, metabolomics and 
many others, each in their own discipline, serve to answer complex biological 
questions by analysing the whole repertoire of components in its entirety [88]. High 
throughput “omics” approaches are widely used to study biological systems. High-
throughput technology is especially powerful in association and causation studies, in 
the identification of genetic mutation, protein biomarkers, metabolic profiling or the 
integration of various omics for disease prediction or prognosis monitoring [89, 90]. 
It is also a good starting basis for personalized medicine in the treatment of highly 
heterogeneous diseases like cancer [91]. 
1.3.1 Metabolomics 
Metabolomics is the identification and quantitation of metabolites within a 
cell, tissue or organism, that provides information about metabolic and bioenergetic 
processes [92]. Gas chromatography mass spectrometry (GC-MS) and NMR 
spectroscopy were  traditionally used for metabolite analysis, but liquid 
chromatography (LC) coupled to electrospray ionization (ESI) mass spectrometry is 
becoming increasingly popular in metabolomics studies due to the ability to “soft 
ionize” large number of metabolites without much fragmentation.  
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In general, metabolomics studies may be classified as one of four approaches 
[93].  1) Targeted metabolite analysis – the study of a primary alteration in a 
biological system directly, which may involve a single metabolite or a cluster of 
metabolites related to the biological system. 2) Metabolic profiling analysis –the 
measurement of a small number of pre-defined metabolites associated with a 
phenotype or diseased state. 3) Metabolomics – involving identification and 
quantitation of the entire repertoire of metabolites that reveal the state of 
metabolome in a biological system and in response to change. 4) Metabolic 
fingerprinting – a rapid high throughput screening of metabolites to differentiate 
samples according to their biological state, to identify unique individuals. 
Metabolomics approaches have been used for various applications in cancer research 
[94]. Various reports on the use of metabolites as potential biomarkers for both 
diagnostic [95, 96] and prognostic [97] applications are also increasingly common.  
Although the metabolic profile of cancer cells may resemble those of rapidly 
proliferating cells, cancer cells may still exhibit unique metabolic signatures. 
Metabolomics is thus a powerful platform for understanding cancer metabolism with 
potential use in cancer diagnosis and prognostic monitoring.  
1.3.2 Proteomics 
Proteomics is the large scale study of proteins to characterize gene function 
and biological processes [98]. The proteome would include the entire set of protein 
species, protein-protein interactions, protein localization and protein complexes [99]. 
The workflow of proteomics can be divided into three aspects - separation, mass 
analysis and data processing.  
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Biological samples are highly complex with large dynamic range and diverse 
protein chemistry [100]. Sufficient separation is therefore critical to “simplify” 
samples for MS-based proteomics study. Depending on the proteomics approach 
chosen, a variety of separation techniques are used. Peptides can be resolved using 
reversed-phase LC, hydrophilic interaction, as well as affinity-based or ion exchange 
chromatography. It is also very common to separate peptides using a combination of 
orthogonal approaches, such as by a 2-dimensional (2-D) approach or 
multidimensional protein identification technology (MudPIT) [101, 102].  
Separation of whole proteins may be performed on 2-D polyacrylamide gel 
electrophoresis (PAGE), where proteins are separated first by iso-electric point and 
then by molecular weight [103]. Fractionation of samples using 2-D gel preserves 
information regarding protein modifications such as phosphorylation, as well as 
truncations, which could be useful in some contexts.  
Mass analysis is typically performed with mass spectrometers that consist of 
three main components: an ionization source, the mass analyzer and a detector. Two 
main ionization methods currently in use are matrix-assisted laser desorption 
ionization (MALDI) and ESI. MALDI uses a laser to impart energy to the analytes 
via the matrix, forming mostly singly positive charged ions [104]. ESI generates 
ions by applying a high voltage across the emitter at the inlet of the mass 
spectrometer. The formation of small charged droplets from the spray undergoes 
evaporation with the conservation of its charges. The decrease in radius of the 
droplets leads to fission due to charge repulsion. Repeated evaporation and fission 
produces very small charged particles and eventually gas-phase ions [105, 106].  
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 Some examples of mass analyzers are the time-of-flight (TOF), quadrupole 
(Q), Fourier transform-ion cyclotron resonance (FT-ICR), orbitrap and ion traps. 
These mass analyzers used different properties to separate ions based on mass-to-
charge (m/z) ratios. For example, TOF analyzer uses flight time of the ions travelling 
in an electric field; the time taken for the ions to arrive at the detector corresponds to 
its m/z. Quadrupole analyzer selects ions by varying electric fields between four rods 
that generate a stable trajectory only allowing ions with a desired m/z to pass 
through [107]. Orbitrap mass analyzer traps ions around a central electrode in an 
electrostatic field, where ions assume a circular trajectories and the m/z is measured 
based on the frequency of harmonic oscillations [108]. These mass analyzers can be 
stand alone or combined in tandem hybrid mass spectrometers such as the Q-TOF 
and Linear ion trap (LTQ)-Orbitrap mass spectrometers. 
Protein abundance can be quantified in a number of approaches. 2D-PAGE 
and 2D Difference gel electrophoresis (2D-DIGE) are gel-based approaches where 
quantitation is made by comparing protein staining intensity or with fluorescence 
labeling. In LC-based proteomics, samples may be labelled with tags such as tandem 
mass tag (TMT) [109], isotope-coded affinity tags (ICAT) [110] or isobaric tags for 
relative and absolute quantitation (iTRAQ) [111, 112]. These tags enable concurrent 
identification and quantitation of proteins from different samples in a single analysis. 
In addition, stable isotope labeling by amino acids in cell culture (SILAC) 
introduced in 2002 also allows labeling of proteins in cell culture systems [113].  
In recent years, label-free quantitative approaches such as spectra counting, 
ion intensity quantitation or selective/multiple reaction monitoring (SRM/MRM) are 
becoming increasingly popular [114]. MRM is a targeted approach where ions from 
a protein of interest are selected and measured [115]. MRM is usually performed on 
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a triple quadrupole MS instrument (QqQ) as only chosen peptides belonging to a 
targeted protein are selected and passed through the first quadrupole. Each of these 
peptides would enter a collision cell where they are fragmented. The pre-chosen 
fragmented ions are again selected to be allowed to pass through the second 
quadrupole and monitored by the mass detector. MRM can be used for accurate 
quantitation of proteins and peptides.  
Two variations of MRM-like approaches are Scheduled MRM high 
resolution (MRMHR) and the Sequential Windowed data independent Acquisition of 
the Total High-resolution Mass Spectra (SWATH-MS) workflow. MRMHR is a 
targeted quantitative proteomics approach performed on a Q-TOF system. By using 
the knowledge of retention time of each peptide during MRM quantitation, many 
more peptides could be monitored in a single MS analysis. A pre-analysis run has to 
be performed to determine and select suitable peptides for every protein that is to be 
quantified. Based on the pre-analysis run, information regarding peptides and 
retention time on all the proteins to be monitored is used to build a method for 
MRMHR.  
SWATH-MS is a non-targeted data independent MS scan of all peptides. 
Instead of monitoring a single peptide, SWATH-MS monitors a windowed mass 
range in sequential increment [116]. During each acquisition windows, all peptides 
are fragmented and the resulting fragments are analyzed and recorded. This process 
is repeated for each sequential overlapping SWATH window until the full mass 
range is covered. As a result, a complete fragment ion map of a sample is recorded. 
With this map, post-data processing is carried out and MRM-like data extraction can 
be performed on any peptide observed in the analysis. In general, label-free 
 22 
 
approaches have the advantage in compatibility with more sample types and are 
more economical by eliminating the need for costly labeling chemicals.  
The enormous volume of data generated from high-throughput experiments 
is another challenge in proteomics. Mass spectrometry vendors often generate output 
with distinct data formats, which further complicate the burgeoning information 
pool.  Integrated data analytical workflow or pipeline have been developed to deal 
with the need for ever-increasing data processing and analysis [117]. These pipelines 
take the forms of automated peptide and protein identification, statistical validation, 
peptide and protein quantitation and functional annotation [118, 119].  
Cancer proteomics - Proteomics in cancer studies may be broadly classified 
into two categories: expression proteomics and functional proteomics studies [120]. 
Expression proteomics studies deal with protein abundance measurements and 
profiling of the proteins with associated isoforms, detecting potential biomarkers for 
early diagnosis and prognostic monitoring. For instance, in prostate cancer, 
proteomics has been used to analyse tissue samples, serum, urine and prostatic fluids 
to identify and validate potential biomarkers that improve specificity and sensitivity 
compared to prostate specific antigen (PSA) that is currently in clinical use [121]. 
Reported in a review, several independent studies in renal cancers commonly 
reported nicotinamide N-methyltransferase (NNMT) as a potential biomarker 
candidate [122].  
Functional proteomics studies, on the other hand, answers more specific 
biological questions in cancer research. Proteomics has been used to unravel novel 
mechanisms of tyrosine kinase signaling [123]. The oncogenic fusion protein Bcr-
Abl is a constitutive active tyrosine kinase involved in chronic myelogenous 
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leukemia [124]. The signaling partners of Bcr-Abl responsible for tumor 
transformation were elucidated through a protein-protein interaction proteomics 
study [125]. Post-translational modifications of protein also associated with  
important biological functions [126]. A study was performed on a large scale to 
quantitatively map phosphorylation events in EGF signaling using 
phosphoproteomics [127]. Proteomic studies of cancer cells also reveal close 
relationships between metabolic changes and cancer pathogenesis by characterising 
changes in metabolic proteins and associated functions [128-130].  
Proteomics is capable of providing novel insights by visualizing the global 
cellular state and capturing information from the whole repertoire of the proteins. 
These may help resolve the complexity of cancer metabolism, and uncover patterns 
in the dynamic proteome indicative of disease.  
1.4 Motivation of study 
Metabolic alteration is a key hallmark of cancer pathogenesis. Understanding 
the intricate mechanisms behind cancer metabolism could lead to novel therapeutic 
advancements in cancer treatment. However, metabolic pathways are highly 
interconnected and under influence of both intrinsic and extrinsic factors. This 
renders the study of cancer metabolism extremely complicated. High throughput 
approaches like proteomics enable characterisation of the overall cell state through 
surveying the whole proteome.  
Anti-tumor effects of FXN have been reported in cancer cell line and mouse 
models and postulated to be involved in modulation of cancer metabolism. 
Proteomics study of FXN knockout mice also showed extensive perturbation of 
proteins involved in energy metabolism [131].  However the mechanism of FXN 
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function in cancer remains largely unknown. Understanding how FXN imposes 
specific regulation on cancer metabolism may provide valuable insights to guide the 
development of novel therapeutic strategies.    
1.5 Aim and Objectives 
In order to unravel the complex function of FXN in cancer cells, a 
quantitative proteomics approach was employed to investigate the proteome changes 
in response to stable FXN over-expression.  
The objectives of study are as follows:  
 To generate stable FXN over-expression (OE) cell lines in the HCT116 cell 
line system.  
 To profile metabolomics and proteomics changes induced by FXN OE. 
 To discover meaningful biological processes perturbed by FXN over-
expression using bioinformatics and pathway analysis. 
 To validate functionally the effect of FXN OE using cell-based assays. 
 To map the mechanisms involved in FXN OE using data generated in this 
study, and test how different pathways could converge and be presented at 















In order to investigate the proteome alterations induced by stable FXN over-
expression, V5-tagged full-length FXN protein was stably over-expressed in 
colorectal cancer cell line HCT116. The construct harbouring FXN-V5 was 
introduced into HCT116 cells by electroporation. Exogenous FXN expression was 
validated by reverse transcriptase (RT)-PCR and immunoblotting. 
2.2 Result  
2.2.1 Over-expression of FXN in HCT116 
2.2.1.1 Plasmid construction and transfection  
To generate FXN over-expressing cells, V5-tagged full-length FXN was 
transfected into colorectal cancer cell line HCT116 (Section 7.1.2). FXN-V5 fusion 
gene was cloned into a commercially available plasmid (gift from Dr. Bi Xuezhi), 
containing blasticidin resistance gene as a selection marker (Fig 2-1). In parallel, a 
second plasmid containing chloramphenicol acetyltransferase (CAT) was used as the 
control. CAT is a bacterial enzyme not expressed in mammalian cells. The plasmids 
were delivered into HCT116 cells using electroporation, a physical transfection 
technique which uses short pulses of high voltage current to induce a transient 





Figure 2-1: Plasmid maps of FXN-V5 and CAT gene. A) Plasmid containing FXN-V5 
was transfected into HCT116. The plasmid contains a blasticidin resistance gene which was 
used for selection. B) The control plasmid contains CAT, a bacterial enzyme not found in 
mammalian cells. 
 
2.2.1.2 Stable cell line selection 
After transfection, the cells were maintained in media containing blasticidin 
for stable cell line selection (section 7.1.3 and 7.1.4). The concentration of 
blasticidin used was determined with a killing assay where wild type HCT116 was 
treated with various concentrations of blasticidin.  
At a dose of 7.5 µg/ml and 10 µg/ml, no cells were found to be growing or 
exhibiting healthy cell morphology. When the concentration of blasticidin was 
reduced to 5 µg/ml, growth was partially inhibited and some features of wild type 
cellular morphology were retained (Fig 2-2). Based on these observations, a 






Figure 2-2: Determination of blasticidin sensitivity. The minimum inhibitory 
concentration of blasticidin in wild type HCT116 was determined by treating HCT116 with 
increasing concentrations of blasticidin. Cell growth was totally inhibited at 7.5µg/ml of 
blasticidin.   
 
Transfected cells were maintained in the selection media until individual 
colonies of cells were visible to the naked eye. These colonies were isolated and 
further expanded, until sufficient cells were accumulated for validating FNX over-
expression. 
2.2.2 Validation of FXN over-expression 
2.2.2.1 Presence of FXN-V5 fusion mRNA 
The presence of FXN-V5 fusion mRNA detected with RT-PCR indicated 
successful transfection and integration of FXN-V5 gene (section 7.7.2). As FXN is 
endogenously expressed in colorectal cells, two pairs of primers were designed to 
distinguish between the endogenous FXN mRNA and FXN-V5 mRNA. The first 
pair consists of a forward primer specific to 5’-end of the FXN cDNA (FXN_F) and 




primers would result in the amplification of a gene product belonging to both 
endogenous FXN cDNA and transfected FXN-V5 fusion cDNA (Fig 2-3). The 
second pair of primer consists of the same FXN_F primer but a reverse primer 
complementary to the V5 tag (V5_R) at the 3’-end, which allows only the 
amplification of a region specific to FXN-V5 cDNA.  
 
 
Figure 2-3: Primer design to distinguish endogenous FXN and FXN-V5 mRNA. The 
primer pair FXN_F and FXN_R would amplify the region corresponding to the endogenous 
FXN cDNA as well as the internal region of FXN-V5 fusion cDNA. The primer pair 
FXN_F and V5_R can only amplify the region belonging to a FXN-V5 fusion cDNA. 
 
FXN-V5 fusion mRNA was detected in HCT116 transfected with the FXN 
construct and not CAT control (Fig 2-4), endogenous FXN mRNA was present in all 
transfected cell lines and CAT control. Genomic DNA contamination was tested to 
be negative by the inclusion of control RT-PCR reactions lacking the reverse 
transcriptase enzyme. As shown in figure 2-4, no bands were observed in lanes 
















Figure 2-4: RT-PCR detects the presence of FXN-V5 fusion mRNA. Two reverse 
primers, FXN_R and V5_R were used to distinguish endogenous FXN and FXN-V5 
mRNAs. All reactions contain FXN_F primer and either FXN_R or V5_R. Bands 
corresponding to FXN-V5 fusion (500bp) were detected in OF1, 5 and 6 and not in CAT 
control. Wild type FXN mRNA was detected in all cell lines. Negative control without 
reverse transcriptase confirmed the absence of genomic DNA contamination.  
 
2.2.2.2 Detection of FXN-V5 recombinant protein 
After the presence of FXN-V5 mRNA was detected, expression of the FXN-
V5 fusion protein was next confirmed. FXN is synthesized as a full-length precursor 
(23kDa) in the cytosol and transported into the mitochondria where it is cleaved in a 
two-step process, resulting in an intermediate form (19kDa) and subsequently the 
matured form (17kDa) [133]. Fusion FXN-V5 protein could be processed into its 
mature/active form in a manner similar to endogenous FXN (Fig 2-5). The addition 
of V5 tag increases the molecular weight by 5kDa, resulting in an intermediate 





Figure 2-5: Immunoblot detection of FXN-V5 fusion protein. Using anti-V5 antibodies, 
recombinant FXN-V5 protein was detected in OF1, 5 and 6 and not in CAT control. FXN is 
synthesis as a precursor and is first cleaved into intermediate FXN-V5 (24kDa) and 
subsequently into mature FXN-V5 (22kDa). 
 
2.3 Discussion 
In this study, three clones containing over-expressed FXN (OF1, OF5 and 
OF6) were used as biological triplicates in order to minimize artefacts due to the 
transfection procedure (random insertion of the recombinant FXN genes into the 
cells) and other biological variations. Herein, only results that showed consistent and 
statistically significant difference in all triplicates were considered valid. This 
experimental setup boosts confidence and robustness in the findings involving 
biological changes as a result of FXN over-expression. 
Secondly, non-functional protein CAT was over-expressed as a control, to 
account for artefacts resulting from the over-expression procedure itself and 
associated overload on the protein synthesis machinery in any biological system. 
This further strengthens the confidence in this study model.  
Western blot showed the FXN-V5 protein product was also processed to its 
immediate and mature form, suggesting that the extent of over-expression has not 








effect of FXN over-expression in HCT116 was investigated using these three FXN 









Chapter 3: Metabolomics and proteomics 





 “Omics” approaches were employed to characterize metabolomic and 
proteome changes in HCT116 cells after FXN over-expression. As FXN is closely 
associated with metabolic pathways, a metabolomics study was performed to 
investigate the regulative effect of FXN on cellular metabolite levels. To enable this, 
metabolite extraction protocol was first optimised before a metabolomics 
comparison was performed between OF and CAT cells.  
In addition, a quantitative proteomics analysis was also carried out to 
identify proteins with altered abundance for further characterization of altered 
biological processes. A 4-plex iTRAQ labeling approach was adopted to 
simultaneously annotate and quantify the CAT, OF1, OF5 and OF6 proteomes. 
Using proteins with altered abundance, pathway enrichment analysis was performed 
to highlight key biological pathways that were altered in OF cells. To verify the 
changes in protein levels identified by iTRAQ, SWATH-MS, a MRM-like approach 
was used.  
3.2 Result 
3.2.1 Optimization of metabolite extraction methodology 
To maximize metabolites extracted from the cells, three different extraction 
methods were tested: i) 80% methanol, ii) 50% ACN and iii) 80% ACN (section 
7.6.1). These solutions were recommended for metabolites extraction from 
mammalian cells in an evaluation study [134]. Extracted metabolites were separated 
by LC on a hydrophilic interaction chromatography (HILIC) column and analyzed 
using a Q-TOF MS. LC gradient was also optimized to enhance separation and 
increase the coverage of metabolites identified. 
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Among the 3 extraction methods, extracting with 50% ACN resulted in 
lowest total ion intensity, indicating the lowest yield while 80% ACN and 80% 
methanol showed similar yields and total ion chromatography (TIC) profiles (Fig 3-
1). However, when metabolites were extracted in triplicate and analyzed, methanol 
extraction gave better reproducibility (Fig 3-2). Therefore, 80% methanol extraction 




Figure 3-1: TIC profile of metabolites with different extraction methods. TIC elution 
profile corresponding to each extraction method as indicated on each panel. Extraction with 
50% ACN produced the lowest total intensity among the three extraction methods. TIC 



















Figure 3-2: Comparisons of extraction showed difference in reproducibility.  TIC 
profile showing 80% methanol (lower panel) had better reproducibility compared to 80% 
ACN (upper panel) when analysed in triplicates. 
 
3.2.2 Metabolomics profiling of FXN OE 
Metabolites from CAT and OF156 were extracted and analyzed as described 
in section 7.6. XCMS online was used to perform data visualization and 








3.2.2.1 Mirror plot shows changes in metabolite profile in OF156 
A mirror plot was generated using XCMS online to compare the metabolite 
profile of OF156 against CAT (Fig 3-3). The mirror plot compares features across 
retention time and displays features that are regulated by more than 1.5 fold as 
circles according to mass-to-charge. Only features with significant fold change 
(p<0.01) were displayed. Green circles indicate fold change >1.5 while red circles 
indicate fold change < -1.5. The size of circle corresponds to Log[fold change], i.e., 
a larger circle represents a greater fold change and a smaller circle indicates a 
smaller fold change. Color intensity represents p-value; a darker circle represents a 
smaller p-value and more significant regulation.    
 
Figure 3-3: Mirror plot depicting changes in metabolite profile. The mirror plot 
illustrates features or peaks with fold change greater than 1.5 and p≤ 0.01. Green circle 
represents an increased fold change; red circle indicates a decreased fold change. The size of 
the circle corresponds to Log[fold change], a larger circle represents a greater fold change. 




3.2.2.2 OF156 and CAT have unique metabolic signatures 
Principle component analysis (PCA) reduces complexity of metabolite 
information and compresses multi-dimensional data in CAT and OF156 to highlight 
similarities and differences between CAT and OF156 (Fig 3-4A). From the PCA 
plot, CAT samples were clustered in the left, away from OF1, 5 and 6 clusters in the 
right. The purpose of multidimensional scaling (MDS) is to provide a visual 
representation of the pattern of proximities (i.e., similarities or distances) within a 
set of samples (Fig 3-4B). From the MDS plot, it is visible that CAT and OF156 




Figure 3-4: CAT and FXN OE have different metabolic signatures. A) Principal 
component analysis showed that CAT is clustered away from OF1, 5 and 6. Each sample is 
analyzed in triplicates; points in red represent runs from CAT and points in blue represent 
runs from OF1, 5 and 6. B) Multidimensional scaling showed CAT and FXN OE possess 
unique metabolic signatures. Each sample is analyzed in triplicates; points in red represent 
runs from CAT and points in blue represent runs from OF1, 5 and 6.  
 
3.2.2.3 Identification of metabolites with altered concentration 
MarkerView™ software was used to quantify the metabolites. A total of 











negative modes. Within 2100 statistically significant peaks that were further 
analysed (p<0.05), about 1000 had good MS/MS spectra, which were manually 
matched using the METLIN database. Out of these, 37 peaks have good matches in 
the database (Fig.3-5; Appendix I).  
 
Figure 3-5: Metabolite identification in METLIN database. A) MS and MS/MS of each 
precursor were used for database matching. When a match is made, the database returns the 
matched ID and a score to measure the quality of the match, adduct of the metabolite, mass 
error of the precursor, structure and spectrum matching. B) Mirror plot of query MS/MS 
spectrum (Top) matched to MS/MS spectrum in the database (Bottom). Teal lines represent 
matched peaks. 
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3.2.2.4 Discussion  
From the mirror plot, a number of features could be observed at the start of 
the gradient. As a hydrophilic column was used to separate the metabolites, these 
features would correspond to highly hydrophobic molecules. Most metabolites 
eluted around the 10 minute mark as observed in the total ion chromatography with 
masses spread across the whole mass range (Fig. 3-3). A smaller number of the more 
hydrophilic metabolites were subsequently eluted at a later time between 20 to 30 
minutes and these tend to be lower molecular weight species, suggesting this group 
to be small polar molecules. 
PCA and MDS plot demonstrated CAT and OF156 exhibited differences in 
metabolic profiles, implying a unique metabolic alteration had occurred as a result 
of FNX OE. Although MDS showed OF1, OF5 and OF6 clustered together, PCA 
revealed slight differences among them. Nonetheless, the small number of 
metabolites identified was not sufficient to conclude the extent of metabolic 
regulation. This could be attributed to a few reasons stated below  
Firstly, available databases are far from complete. Identification of a 
metabolite relies on accurate mass in MS as well as knowledge of the fragmentation 
pattern produced during MS/MS. Existing databases often lack MS/MS spectra for 
many metabolite precursors and fail to capture slight differences in fragmentation 
pattern produced by different mass analyzers. Secondly, spectra matching software 
are severely lacking. Identification of metabolites in this study was performed 
manually for each metabolite precursor and its MS/MS spectrum individually. 
Thirdly, coverage of metabolites detected were limited as seen in Fig 3-1 and 
discussed earlier in this section. The separation of the metabolites could be 
improved as the highly hydrophobic species were eluted within the first minutes, 
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hardly with any separation. Due to the high complexity of metabolites, a pre-
fractionation step would be ideal for improving coverage. High diversity of 
metabolite species also leads to the differential ionization efficiency issue and 
detection of these species. 
To summarize, triplicates of FXN OE cells showed concerted differences in 
their metabolic profile compared to CAT control, highlighting a major shift in 
cellular metabolism from FXN over-expression. In addition, metabolic analysis was 
able to identify and quantify both oxidized and reduced form of glutathione. This 













3.2.3 iTRAQ proteomics profiling of FXN OE 
3.2.3.1 Reproducibility in OF156 biological triplicates 
In order to determine if the biological triplicates OF1, OF5 and OF6 were 
reproducible in iTRAQ quantitation, a regression analysis was performed. Log fold 
change of all peptides identified from each sample were plotted against one another, 
as shown in Fig 3-6. Based on the r2 value of 0.7507 to 0.8692, a fairly good 
correlation was obtained. This indicates that reproducibility in MS analysis was 
good within the three biological triplicates.   
 
Figure 3-6: OF156 biological triplicates showed high reproducibility in iTRAQ. 
Regression plots of FXN OE triplicates. A) Log fold change of OF1against OF5, r2 = 0.8692. 







3.2.3.2 Summary statistics and cutoff threshold 
In the iTRAQ analysis, a total of 2313 proteins were identified with unused 
protein score ≥1.3 (95% confidence). Proteins with changes in abundance were 
determined by the following statistical cut-offs: (i) proteins identified by a single 
peptide were removed from the analysis; (ii) a cut-off threshold ratio of greater than 
or equal to1.3, or less than or equal to the reciprocal value (0.77) was used [135]; (iii) 
Only proteins with ratios that met the threshold in all three biological triplicates 
were considered as having altered abundance (Table 3-1). By applying these 
selection criteria, differential abundance of 276 proteins were detected. Among these, 
146 were increased while 130 had a reduction in protein level (Appendix II).  
Table 3-1: iTRAQ summary statics. 
Filtering criteria Protein 
Protein identified with protein score ≥ 1.3† 2313 
Total protein change 276 
Increased protein level (≥1.3) 146 
Decreased protein level (≤0.77) 130 
    †False discovery rate of protein identification is less than 1%. 
 
The coefficient of variation between biological triplicates was also calculated 
to determine the consistency of fold change. The average coefficient of variation 
was 21.46%, indicated relatively consistent fold changes among OF156.  More than 
90% of these 276 proteins have a coefficient of variation of less than 40%, and 





Figure 3-7: Coefficient of Variation between biological triplicates. Boxes in bar chart 
displaying coefficient of variation of log fold change between biological triplicates. Left 
axis represents the cumulative percentage of proteins with altered abundance. Right axis 
represents number of proteins. More than 90% of proteins have a coefficient of variation 
less than 40%. Average coefficient of variation is 21.46%. 
 
3.2.3.3 Uniprot keyword of proteins with differential abundance 
In order to visualize changes in protein abundance induced by FXN over-
expression, these proteins were mapped using Uniprot keywords (Fig 3-8). The 
UniProt keyword is a set of controlled vocabulary developed to describe and assign 
functions to each protein. Majority of these proteins are involved in transport, 









































cycle, DNA damage response, apoptosis and differentiation. There is also a group of 
proteins that are involved in a variety of metabolic processes such as protein 
biosynthesis, lipid metabolism, amino-acid biosynthesis. These keywords describe 
the function of the perturbed proteins providing insights to the effects of FXN over-
expression.  
 
Figure 3-8: Proteins with altered abundance, stratified by Uniprot Keywords.  Number 
of proteins with differential abundance in FXN OE annotated by each Uniprot keyword. 
Uniprot keywords are derived from a controlled vocabulary, similar to gene ontology. 
 
3.2.3.4 KEGG pathway enrichment using DAVID 
A pathway enrichment analysis was performed using Database for 
Annotation, Visualization and Intergrated Discovery (DAVID), a web-based 
annotation and analysis software. Using statistical tools, DAVID maps proteins that 
are over-represented in the present dataset to Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) pathways (Fig 3-9).  








































Figure 3-9: KEGG pathways over-represented by proteins with altered abundance. 
The pathways listed on the vertical axis are pathways which are significantly enriched (a 
modified Fisher’s Exact test, EASE score <0.01). The horizontal axis denotes the number of 
proteins in each of the pathways listed.  
 
Briefly, enrichment analysis may be understood as significantly higher 
number of proteins belonging to a biological pathway or process compared to an 
expected value of the dataset, as if the dataset were generated from random sampling 
of the proteome. Pathways such as TCA cycle, cell cycle and OXPHOS were 
significantly enriched in the present dataset, and these groups of related proteins 
present in our dataset were not due to random occurrences. 
3.2.3.5 Verification of iTRAQ with SWATH™ 
Data acquired from SWATH analysis were subjected to similar cutoff 
criteria to shortlist proteins that have differential abundance. Proteins must have a 
threshold ratio of greater than 1.3 or less than its reciprocal value (0.77), and show 
























consistent ratio in the same trend for all triplicate OF1, OF5 and OF6. From a total 
of 1985 proteins identified, 331 were found to have differential abundance. This list 
features an overlap of 19 proteins that were also significantly changed in the iTRAQ 
analysis, of which, ratios of 13 proteins agree with iTRAQ data (Fig 3-10). These 
proteins are presented in Appendix III.  
 
Figure 3-10: Venn diagram depicting overlap between iTRAQ and SWATH™ 
analyses. A total of 331 and 276 proteins were found to be differentially altered in SWATH 
and iTRAQ analysis respectively. 19 of these proteins were found in both methods, of 
which, 13 proteins were validated.  
 
3.2.3.6 Discussion 
In this study, a quantitative proteomics approach was used to elucidate the 
effect of FXN OE. The experimental design and method of data analysis boosted the 
confidence of identifying true biological changes. The use of biological replicates 
and only including common proteins as part of highly stringent selection criteria 
facilitated the identification of true biological events against background “noise” due 
to biological variations. OF156 had reproducibility in total peptide quantitation and 












targets demonstrated consistent biological effects which further augmented the 
quality and confidence of the findings.  
The use of UniProt keywords is an easy and quick method to visualize the 
overall characteristics and functions of regulated protein targets, giving a hint into 
perturbed biological functions. Pathway enrichment analysis determines how these 
proteins relate to each other, by highlighting over-represented groups of proteins in 
common pathways or biological processes. Identifying biological pathways 
associated from these clusters of proteins provided more meaningful information 
than looking at individual protein functions.   
From pathway enrichment analysis, pathways in cell cycle, OXPHOS and 
TCA cycle became the focus of this study. Considering the function of FXN, these 
pathways can be affected by FXN over-expression and could be the mechanism 
behind its anti-cancer effect. However, there is a need to further verify the iTRAQ 
result before any valid conclusion could be drawn. 
Current MRM-like workflows available on hybrid QqTOF instrumental 
setup are the MRMHR and SWATH-MS workflow as described in section 1.3.2.  For 
both of these workflows, a common drawback is the lack of adequate interrogation 
for complex samples such as mammalian cell lysate. Both methodologies are 
currently performed on a 1-D LCMS platform. Without sufficient separation, desired 
peptides are often not detected in a complex sample, especially considering that the 
iTRAQ experiment was performed on a 2-D LCMS platform. However, SWATH-
MS is capable of recording the maximum information regarding each sample, 
increasing the chance of successfully detecting desired peptides. SWATH 
acquisition also allows a retrospective interrogation of data in the future in the event 
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of new questions raised. Out of the two workflows, SWATH-MS was chosen for 
verification of the iTRAQ targets. 
After data were acquired from SWATH acquisition, similar criteria were 
applied to isolate proteins with significant changes in abundance. This list of 
proteins was compared to the iTRAQ result. Nineteen proteins out of 276 iTRAQ 
targets were detected in the SWATH analysis and the abundance trend of 13 
proteins were successfully verified. The low amount of overlaps could be attributed 
to a few reasons. 
 Analytical method – Firstly, iTRAQ is an information dependent acquisition 
whereas SWATH is a data independent approach. The algorithms for peptide 
selection during analysis are vastly different. Secondly, collision energy parameters 
used for fragmentation in iTRAQ and SWATH are different. This could lead to 
different fragmentation patterns even for the same peptides, resulting in a different 
set of total peptides identified and proteins hits from search algorithms.     
Separation of samples –  iTRAQ analysis was performed using 2-D LC 
separation while SWATH uses single reversed-phase LC separation, which likely 
has insufficient resolving power for complex samples. This resulted in a very 
different set of proteins identified.  
Differences in sample – the major difference in sample would be the 
presence of the iTRAQ reagents linked to each peptide, which potentially changes 
the size of the peptides and chemistry of the sample. Loading of peptides on to the 
column and subsequent elution step could be affected as the iTRAQ reagent could 
change the hydrophobicity of peptides. Moreover, the label moiety also affects the 
amount of collision energy absorbed and the fragmentation patterns [136]. 
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 The changes in protein level of many iTRAQ targets were unable to be 
validated due to the lack of overlapping proteins identified in both methods. 
Therefore, presented in the next chapter of the thesis, functional assays were 
performed to validate the biological processes from iTRAQ findings as well as to 









Chapter 4: Functional validation of proteome 





Inhibition of tumor growth by FXN over-expression was demonstrated in 
various studies as discussed before. However, the exact mechanism of the anti-
tumor effect was not known. In order to understand the molecular mechanism 
behind the phenotypic changes associated with FXN over-expression, proteome of 
HCT116 over-expressing FXN was characterized. HCT116 was used as a platform 
to investigate the changes induced by FXN over-expression since it is a well-studied 
colorectal cancer cell line. Based on the iTRAQ dataset, key biological networks and 
their protein components that are of relevance to the cancer phenotype were 
highlighted. In this section, changes in OXPHOS, redox status and cell cycle/cell 
proliferation were examined to further analyse and functionally validate the iTRAQ 
findings. 
4.2 Results 
4.2.1 Cell cycle and cell proliferation 
Cell cycle progression and proliferation are key biological processes 
highlighted in pathway analysis of the iTRAQ data. A number of proteins related to 
cell cycle and growth were perturbed due to the over-expression of FXN. One such 
protein that is directly associated with cell cycle is cyclin dependant kinase 4 
(CDK4). CDK4 was found to be elevated (2.164 ± 0.563) in OF cells. The role of 





4.2.1.1 OF cells have increased CDK4 and cyclin D protein level 
CDK 4 forms a complex with cyclin D in early G1 phase of the cell cycle. 
The protein level of CDK4 and cyclin D were validated independently using western 
blotting (Fig 4-1). Both iTRAQ and western blot data confirmed the increase in 
protein levels of CDK4 and cyclin D in OF1, OF5 and OF6.  
 
Figure 4-1: G1 phase markers are elevated in OF cells. A) Immunoblotting of cell cycle 
protein CDK4 and cyclin D showed higher protein level in FXN OE cells. Actin is used as 
the internal loading control. B) Histogram shows densitometric measurement of the fold 












4.2.1.2 Proliferation assay shows growth inhibition in OF cells 
Since changes in the levels of cell cycle markers were observed, a 
proliferation assay was performed to measure the growth rate of CAT and OF cells 
(section 7.2.2). OF cells exhibited a significantly lower proliferation rate compared 
to CAT (Fig 4-2) by 48 hrs after seeding. The same growth inhibition persisted to 72 
hours. Growth rates of the FXN OE triplicates were similar and showed no 
significant differences among them. 
 
Figure 4-2: Growth inhibition of FXN OE cells. Cell proliferation assayed over a course 
of 72hr. FXN OE cells had a lower proliferation rate compared to CAT control cells. 
Columns represent mean from triplicates and error bar represents S.D.,*** p<0.001 
 
4.2.1.3 FXN OE induces p21/ p27 and decreases late G1 phase proteins. 
The abundance of other cell cycle proteins was determined using western 
blot to further elucidate the role of FXN over-expression in the perturbation of cell 
cycle (Fig 4-3). p21 and p27 are cell cycle inhibitors that interact and inactivate 
various CDKs and cyclins [137], thereby inhibiting cell cycle progression.  























Figure 4-3: p21 and p27 inhibit expression of late G1 phase proteins. A) Immunoblot 
depicting higher levels of cell cycle inhibitors p21 and p27 in FXN OE cells. Late G1 phase 
proteins CDK2 and cyclin E are lower in FXN OE cells. B) Histogram shows densitometric 
measurement of the fold change in respective cell cycle protein level compared to CAT 
control. * p<0.05, ** p<0.01 
 
Immunoblotting analysis demonstrated that the protein level of p21 and p27 
were increased in OF1, OF5 and OF6, providing alternative explanation for the 
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inhibition of cell cycle. CDK2 and cyclin E are late G1 phase cell cycle proteins that 
are involved in G1 to S phase transition. Western-blot analysis also showed that 
FXN OE reduced the protein level of CDK2 and cyclin E compared to CAT control. 
4.2.1.4 FXN OE inhibits G1 exit 
Increase in cell cycle inhibitors and decrease in late G1 phase cell cycle 
proteins further suggest that FXN OE could modulate the cell cycle. In order to 
investigate perturbations to the cell cycle, cell cycle analysis was performed (section 
7.3.1). Population of cells in each cell cycle phase was determined using propidium 
iodide (PI), which stains cellular DNA and the amount of DNA was quantified by 
flow cytometry. Using ModFit™, a cell cycle profile modeling software, the 
distribution of cells in each cell cycle phase was determined (Fig 4-4A). OF1, OF5 
and OF6 showed a significant increase in the proportion of cells in G1 phase and a 
correspondingly lower proportion of cells in S phase, clearly suggesting a delay in 





Figure 4-4: FXN OE cells had an extended G1 phase. A) Representative plot of cell cycle 
analysis using ModFiT™ modeling software. Percentage of cells in various cell cycle 
phases was determined by model fitting. B) Histogram shows the percentage of cells in each 
cell cycle phase for OF1, 5, 6 and CAT. FXN OE cells had a significantly prolonged G1 
phase compared to CAT control. Columns represent mean from three flow cytometry 







4.2.1.5 Decreased cell proliferation could be due to G1 inhibition 
During cell division, CDK4/cyclin D complexes accumulate in G1 phase and 
phosphorylate the RB protein. Hyperphosphorylated RB is deactivated and no 
longer binds to E2F, allowing the transcription of various cell-cycle genes such as 
CDK2 and cyclin E. The activities of these cell cycle proteins in turn further 
regulate the cell cycle progression  [6, 138, 139]. CDK2/cyclin E complexes further 
phosphorylate and maintain the hyperphosphorylated state of RB protein in late G1 
phase.  
Cyclin E is also reported to exist in several low molecular weight (LMW) 
isoforms (34-49 kDa) in cancer cells. Interestingly, these LMW cyclin E have been 
associated with poor prognosis and higher recurrence in clinical colorectal cancer 
samples [140, 141]. p21 and p27 are members of the Cip/Kip family, known to be 
negative regulators of cell proliferation and are considered to be tumor suppressors. 
LMW forms of cyclin E are hyperactive and remain functional even with the 
inhibition from p21 and p27, thus causing disruption of the G1/S checkpoint [142].  
In section 4.2.1.1, increased CDK4 level identified in iTRAQ was verified 
using western blotting. Since cyclin D is closely related to the function of CDK4, 
protein level of cyclin D was also determined by immunoblotting. As FXN OE 
increases the level of both CDK4 and cyclin D, OF cells should divide more actively 
compared to CAT cells, resulting in higher growth. However, when a proliferation 
assay was performed, contradictory result was obtained, where FXN OE cells 
instead exhibited a lower proliferation rate. When the abundance of cell cycle 
inhibitor p21 and p27 were found to be up-regulated in OF cells and the late G1/S 
phase CDK2/cyclin E (LMW) were decreased, it became apparent that G1 phase in 




Figure 4-5: Cell cycle proteins perturbed in FXN OE. Figure shows cell cycle proteins 
with altered abundance in FXN OE cells. Cyclin D, CDK4, p21 and p27 protein levels were 
elevated while cyclin E and CDK2 protein levels were decreased. Cyclin D and CDK4 
proteins are early G1 phase cell cycle proteins, while cyclin E and CDK2 are late G1 phase 
cell cycle proteins. p21 and p27 are cell cycle inhibitors.  
 
Cell cycle analysis by flow cytometry was able to confirm that OF cells 
indeed had a prolonged G1 phase compared to CAT cells. This caused a shift in the 
population of OF cells, accounting for the higher proportion of cells in G1 phase and 
a correspondingly lower proportion progressing to the S phase. The inhibition of cell 
cycle thus likely occurs during the late G1 phase, delaying the transition of cells 
from G1 into S phase. In summary, over-expression of FXN in HCT116 cells 



















4.2.2 OXPHOS and TCA cycle  
Data from iTRAQ also revealed changes in the level of a number of proteins 
associated with the ETC and TCA cycle. FXN plays an important role in the 
regulation of mitochondrial OXPHOS [74, 143]. In this section, the role of FXN OE 
in promoting OXPHOS is discussed. Specifically, the effect of FXN OE on the 
abundance of OXPHOS proteins is demonstrated.  
4.2.2.1 iTRAQ revealed OXPHOS and TCA cycle proteins 
A number of proteins involved in OXPHOS were found to be altered in OF 
cells, including proteins from all five complexes of the ETC (Table 4-1). Complex I, 
also known as NADH dehydrogenase, is involved in transferring electron from 
NADH to ubiquinone and translocation of H+ across the inner mitochondrial 
membrane. Succinate dehydrogenase subunit B (SDHB) is a hydrophilic subunit of 
the complex II. Succinate dehydrogenase is involved in the transfer of electrons 
from succinate via FADH2 to ubiquinone. In complexes III and VI, electrons are 
transferred to O2 via cytochrome C with the translocation of H+ across the inner 
mitochondrial membrane. Complex V, ATP synthase, utilizes the electrochemical 
gradient generated to drive the synthesis of ATP [21]. 
Based on iTRAQ data, the abundance of seven proteins involved in the TCA 
cycle were altered in OF clones (Table 4-2). TCA cycle connects glucose 
metabolism to OXPHOS. Briefly, isocitrate dehydrogenase catalyzes the conversion 
of isocitrate to α-ketoglutarate, which is subsequently converted to succinyl-Co-
enzyme A (CoA) by 2-oxoglutarate dehydrogenase. Succinyl CoA is then catalysed 
to succinate by succinyl-CoA ligase while generating GTP in the process. Lastly, 










† Peptides Fold change# (±S.D.) 
I IPI00028883 NADH dehydrogenase 1 beta subcomplex subunit 8 2 1.505 ± 0.329
I IPI00946474 NADH dehydrogenase 1 alpha subcomplex subunit 5 3 1.545 ± 0.121
I IPI00945153 NADH dehydrogenase 1 alpha subcomplex subunit 6 2 -1.599 ± 0.033
II IPI00294911 Succinate dehydrogenase iron-sulfur subunit 8 1.623 ± 0.174
III IPI00029264 Cytochrome c1 9 -1.964 ± 0.167
IV IPI00021785 Cytochrome c oxidase subunit 5B 8 -1.372 ± 0.112




†The list contains significantly altered proteins related to electron transport chain. All these proteins have met the criteria as 
mentioned in section 3.2.3.1. 











† Peptides Fold change# (±S.D.) 
IPI01011396 Isocitrate dehydrogenase subunit gamma 3 -1.752 ± 0.217
IPI00030702 Isocitrate dehydrogenase subunit alpha 7 -1.677 ± 0.061
IPI00945507 Succinyl-CoA ligase  [GDP-forming] subunit beta 2 -1.561 ± 0.244
IPI00872762 Succinyl-CoA ligase  [GDP-forming] subunit alpha 5 -1.479 ± 0.087
IPI00464979 Succinyl-CoA ligase  [ADP-forming] subunit beta 3 1.714 ± 0.172
IPI00294911 Succinate dehydrogenase iron-sulfur subunit 8 1.623 ± 0.174
IPI00926925 2-oxoglutarate dehydrogenase 2 -1.664 ± 0.290
†The list contains significantly altered proteins related to TCA cycle. All these proteins have met the criteria as 
mentioned in section 3.2.3.1. 
# Fold change of protein levels in OF cells compared to CAT control 
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4.2.2.2 FXN OE induces OXPHOS 
In order to determine the functional impact of these altered protein levels 
(Table 4-1 and Table 4-2), the rate of OXPHOS in FXN OE and CAT cells was 
measured (section 7.3.2). The mitochondrial membrane potential is an important 
parameter for OXPHOS in mitochondrial ATP production that directly affects the 
rate of OXPHOS [144, 145]. To quantify differences in OXPHOS between OF and 
CAT control cells, the mitochondrial membrane potential of each cell line was 
measured using JC10 fluorescent dye.  
JC10 is a cationic, lipophilic dye which is specifically loaded into the 
mitochondria. A higher mitochondrial membrane potential would cause more dye to 
accumulate and be retained in the mitochondria. Mitochondrial accumulation of the 
dye causes a reversible aggregation, which shifts the emission wavelength from 520 
nm to 570 nm. All three OF cell lines showed higher ratio of aggregated-red dye to 
green dye when compared to CAT control, indicating that FXN OE increases 
mitochondrial membrane potential, which can be interpreted as an increased rate of 
OXPHOS (Fig. 4-6).  
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Figure 4-6: OF cells have higher OXPHOS. Histograms show the ratio of red to green 
signal of JC-10. JC-10 staining measures mitochondrial membrane potential, which is an 
indication of OXPHOS. Columns are mean from three flow cytometry experiments; bars 
represent S.D; *, p< 0.05; **,p< 0.01; ***,p< 0.001. 
 
4.2.2.3 ATP5O and SDHB may be involved in FXN-induced OXPHOS 
The iTRAQ analysis revealed changes in the level of several proteins 
associated with OXPHOS (Table 4-1 and Table 4-2). However, these proteins show 
varying trends of regulation. In order to determine the overall effect of these changes, 
the collective function of this group of proteins was assayed by JC10. The combined 
impact of these protein changes should be responsible for increasing OXPHOS in 
FXN OE cells. Although it is difficult to pinpoint the role of specific OXPHOS 
proteins or link any phenotypic change to all the proteins involved, several possible 
candidates that provide explanation for increased OXPHOS are highlighted below. 
ATPase synthase is an ETC complex involved in the last step of ATP 
production during OXPHOS. ATPase synthase subunit O (ATP5O) protein level 
was found to be higher in FXN OE cells (1.840 ± 0.118). The role of ATP5O in 
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ATPase synthase in not known except for that this subunit could be involved in the 
regulation of glucose uptake [146], which is a factor promoting OXPHOS in FXN 
OE cells. 
Succinate dehydrogenase (SDH) consists of four subunits (denoted as A to D) 
and is found on the inner mitochondrial membrane (Fig 4-7).  
 
 
Figure 4-7: Succinate dehydrogenase functions at the crossroad of TCA cycle and ETC. 
Illustration showing the pivotal position of succinate dehydrogenase in OXPHOS. SDH 
catalyzes the conversion of succinate to fumarate. SDH is also involved in feeding electron 
to the electron transport chain via iron sulphur cluster and Q enzyme. Figure reproduced 
from Gottlieb and Tomlinson [147] with permission. 
 
SDH is a TCA cycle enzyme, as well as complex II of the ETC, that 
catalyzes the dehydrogenation of succinate to fumarate, by transferring two 
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hydrogen atoms from succinate to FAD subunit A. In this way, FAD is reduced to 
FADH2, which releases a pair of electrons to the three iron sulfur centers in subunit 
B of SDH and subsequently to ubiquinone (Q), reducing it to the ubiquinol (QH2) 
[147]. 
SDH functions as a second ETC entry point for electrons from the TCA 
cycle and plays a critical role in energy metabolism through its dual function in the 
TCA cycle and ETC. Based on iTRAQ data, SDHB protein level was found to be 
elevated in OF cells (1.623 ± 0.174). This increase may be due to FXN’s 
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4.2.3 Change of cellular redox homeostasis in OF cells 
ROS may be generated as byproducts of OXPHOS, and these could cause 
oxidative damage to the cells. Since FXN OE increases OXPHOS, the oxidative 
stress associated with oxidative ATP production is in question. This section presents 
data supporting that over-expression of FXN leads to increased levels of anti-
oxidant enzymes, and higher capacity for ROS scavenging. OF cells also have lower 
intracellular ROS level and increased resilience towards exogenous ROS insult.  
4.2.3.1 OF cells have lower resting ROS levels 
Intracellular ROS levels in OF and CAT cells were measured using a 
fluorescence dye 2',7'-dichlorfluorescein-diacetate (DCFH-DA) as described in 
section 7.3.3. After the membrane permeable DCFH-DA enters the cells, the 
hydrophobic diacetate group is cleaved by nonspecific intracellular esterases, thus 
trapping the dye within the cells. Oxidative species in the cells will then oxidize the 
DCFH to fluorescent DCF. The intensity of DCF fluorescence corresponds to the 
amount of ROS in the cells. As quantified by flow cytometry, OF cells exhibited 
lower DCF fluorescence intensity as compared to control CAT cells, indicating less 











Figure 4-8: OF cells have lower intercellular ROS levels. Histograms show average 
fluorescence intensity of DCHF signal in OF1, 5, 6 compared to CAT. Higher intensity 
represents higher endogenous ROS levels. Columns represent mean from three flow 
cytometry experiments; bars represent S.D; **, p< 0.001. 
 
4.2.3.2 FXN OE increases anti-oxidant enzymes  
In the iTRAQ analysis, a number of peroxiredoxins, glutathione peroxidase 








Table 4-3: Altered proteins involved in cellular oxidative redox homeostasis  
Accession 
No. Protein name†
 Peptides Fold change# (±S.D.) 
IPI00220301 Peroxiredoxin-6 6 1.311 ± 0.068
IPI00024919 Peroxiredoxin-3 38 -1.571 ± 0.119
IPI00000874 Peroxiredoxin-1 42 1.500 ± 0.051
IPI00910821 Glutathione peroxidase 8 3 1.558 ± 0.078
IPI00646689 Thioredoxin domain-containing protein 17 3 1.882 ± 0.223
 †The list contains significantly altered proteins that are anti-oxidant enzymes. All these proteins have met the 
criteria as mentioned in section 3.2.3.1. 
# Fold change of protein levels in OF cells compared to CAT control 
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Peroxiredoxins are a family of anti-oxidant enzymes containing highly 
conserved cysteine active-sites and sequence. Peroxiredoxins can be found in the 
cytosol, nucleus and mitochondria and share the same catalytic action in the removal 
of peroxides [148]. Members of the glutathione peroxidase family usually contain 
selenium in the redox center, but newer members were found to contain cysteine in 
its active site [149]. Glutathione peroxidases catalyze the removal of hydrogen 
peroxide with the use of glutathione as co-factor [150]. Thioredoxins on the other 
hand are part of the thioredoxin systems involving thioredoxin reductase and co-
factor NADPH. Thioredoxins mainly contain dithiol/disulfide active sites and are 
involved in the reduction of disulfide bonds. Thioredoxins are also essential for 
synthesis of deoxyribonucleotides during cell proliferation [151]. 
In addition to anti-oxidant properties and the ability to ameliorate oxidative 
stress, these enzymes have also been reported to play a significant role in signal 
transduction. Numerous biological processes such as inflammation, apoptosis, 
growth and survival also depend on peroxides such as hydrogen peroxide as 
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4.2.3.3 Anti-oxidant proteins in OF cells reduce intracellular ROS 
In order to ascertain if the reduction of intracellular ROS is due to enhanced 
anti-oxidant scavenging, the glutathione redox system was investigated since it is 
one of the most important peroxide scavenging systems in the cell. By 
immunoblotting, increased abundance of glutathione peroxidase 1 (GPx1) protein 
was validated in FXN OE cells compared to the CAT control (Fig 4-9).    
 
Figure 4-9: FXN OE cells have higher levels of GPx1. A) Immunoblotting shows higher 
levels of GPx1 protein in FXN OE cells. Actin is used as an internal loading control. B) 
Histogram shows densitometric measurement of the fold change of GPx1 in FXN OE cells 
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4.2.3.4 Activated GSH redox system reduces ROS levels in OF cells 
In the glutathione redox system, reduced glutathione (GSH) is a cofactor in 
the removal of oxidative species catalyzed by glutathione peroxidase. As byproduct, 
oxidized glutathione (GSSG) is generated, but it should be rapidly converted back to 
GSH. The ratio of GSH to GSSG reflects the activity of the glutathione redox 
system and constitutes a key indicator of the intracellular redox environment [154].  
In section 3.2.2, a metabolomics profiling that was performed in FXN OE 
cells compared to CAT controls also quantified the level of GSH and GSSG as 
metabolites. Using these data, the ratio of GSH to GSSG was calculated. OF1, OF5 
and OF6 all had lower GSH/GSSG ratios than CAT (Fig 4-10).   
 
 
Figure 4-10: FXN OE cells have lower GSH/GSSG ratio. Histograms show average 
GSH/GSSG ratio calculated from XIC areas of GSH and GSSG in the metabolomics 
analysis. Bars represent the mean GSH/GSSG ratio from triplicate runs; error bars represent 
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4.2.3.5 OF156 are more resistant to ROS insult 
Given the different capacity to react against oxidative stress described in 
previous sections, the effect of exogenous ROS insult on OF cells was investigated. 
CAT and OF cells were treated with increasing doses of tert-butyl hydroperoxide 
(TBHP), a stable analogue of hydrogen peroxide (section 7.2.3). OF cells showed 
significantly higher resilience to TBHP compared to CAT from 40µM of TBHP 
onwards (Fig 4-11).  
 
Figure 4-11: OF156 showed increased resistance to TBHP. Histograms showing 
percentage survival of cells after treatment with TBHP. FXN OE cells showed significantly 
higher survival from 40µM of TBHP onwards, columns represent mean percentage survival 
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4.2.3.6 FXN OE activates ROS scavenging and alters redox status  
Low antioxidant defense and high oxidative status are established hallmarks 
of many cancers [155]. Based on iTRAQ analysis, numerous peroxiredoxins, 
glutathione peroxidase and thioredoxin related proteins were identified with higher 
abundance in OF cells (Table 4-3). This group of antioxidant enzymes play pivotal 
roles in oxidative homeostasis and the regulation of redox signaling [152, 156, 157], 
and could also in turn regulate cancer metabolism and contribute to anti-tumor effect 
of FXN over-expression. 
 
Figure 4-12: FXN OE cells possess better ROS scavenging activity. Higher level of 
GSSG and glutathione peroxidase enzyme coupled with lower intracellular ROS suggested 
the red arrow in the above pathway is more active in FXN OE cells. 
 
OF cells have higher OXPHOS which could lead to increased generation of 
ROS in the ETC complexes [158]. However, the experimental observation from this 
study appears to contradict this proposition, since lower intracellular ROS was 
detected in OF cells compared to CAT. Low ROS levels could be a result of 
increased antioxidant enzymes such as GPx1 [85]. Indeed, this was confirmed by 
higher GPx1 level, suggesting that GPx1 may be catalyzing the removal of ROS 
such as H2O2, leading to an accumulation of GSSG. Enhanced resistance of OF cells 


















Chapter 5: Tumor suppressive function of FXN 
may be via HIF-1α destabilization 
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5.1 Introduction 
HIF-1α is a key molecule in cancer cell metabolism. iTRAQ characterization 
of FXN OE seems to converge on HIF-1α as well. This section shows that OF cells 
have lower HIF-1α level and possible regulation of HIF-1α level in OF cells. 
Extracellular matrix metalloproteinase inducer (EMMPRIN) is a HIF-1 target and 
identified in the iTRAQ analysis. Its role in modulating metabolic changes and anti-
cancer effect of FXN OE is also discussed. 
5.2 Result 
5.2.1 HIF-1α is destabilized in OF cells 
Several pieces of evidence in this study appear to describe hypoxic changes: (i) 
HIF-1α is a regulator of the metabolic switch; (ii) higher SDHB should regulate 
HIF-1α level; and (iii) ROS play intricate roles in hypoxia.  
In view of these, it was hypothesized that FXN OE could lead to a change in 
hypoxia state in HCT116. To substantiate this claim, the protein level of HIF-1α was 
measured by western blotting. As shown in Fig 5-1, FXN over-expressing cells 
indeed have lower endogenous HIF-1α level.  
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Figure 5-1: Lower HIF-1α level was detected in FXN OE cells. A) Immunoblotting 
showed lower HIF-1α protein levels in FXN OE cells. Actin is used as internal loading 
control. B) Histogram shows densitometric measurement of the fold change of HIF-1α in 
FXN OE cells compared to CAT control. * p<0.05  
 
5.2.2 Western-blot and MRM validation of decreased EMMPRIN level 
The reduced protein level of EMMPRIN (-1.612 ± 0.035) was verified in OF 
cells by immunoblotting. A lower level of EMMPRIN protein was consistently 
detected in all OF1, OF5 and OF6 (Fig 5-2). As EMMPRIN may be glycolysated, 
several bands are detected in western blots. The abundance of EMMPRIN in FXN 
clones and CAT was further verified by SWATH in section 3.2.3.5. Three peptides 
belonging to EMMPRIN were quantified based on the area under the curve (AUC) 









Figure 5-2: FXN OE cells had lower EMMPRIN levels. A) Immunoblotting showed 
lower EMMPRIN protein levels in FXN OE cells. Actin is used as an internal loading 
control. B) Histograms show densitometric measurement of the fold change of EMMPRIN 
in FXN OE cells compared to CAT control. ** p<0.01 
A
B
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Figure 5-3: Representative XICs showing lower EMMPRIN in FXN OE cells. Each 
panel shows the overlay of three transitions of the peptide AAGTVFTTVEDLGSK from the 
protein EMMPRIN. The scales of the axis in all four panels are standardised. CAT shows 
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Figure 5-4: Total peak area of EMMPRIN.  Histograms show total peak area of 
EMMPRIN in FXN OE and CAT cells as identified and quantified in SWATH. Columns 
represent mean from triplicate runs; error bars represent S.D.; *** p<0.001 
 
5.3 Discussion 
Experimentally, reduction in HIF-1α level in OF cells was observed, and it 
could be rationalised by numerous changes at protein and metabolite levels. This 
section discusses how FXN over-expression could lead to reduced HIF-1α levels and 
how lower HIF-1α could explain phenotypic changes observed in OF cells.  
5.3.1 Succinate dehydrogenase B may play a role in HIF-1α regulation 
As discussed in section 4.2.2.4, SDHB potentially affects TCA cycle as well 
as OXPHOS. SDH is a well-established mitochondrial tumor suppressor, loss-of-
function mutation in SDH subunits leads to an accumulation of succinate which may 
leak into the cytosol to cause inhibition of prolyl hydroxylases (PHD) [159]. 
Inactivating PHD leads to the stabilization of HIF-1α in a pseudo-hypoxia condition. 
Defective SDH is associated with a number of malignancies such as gastrointestinal 
stromal cell tumor, renal carcinoma, as well as gastric cancer, and familial head and 
neck paragangliomas [160-164]. The anti-tumor effect of SDHB subunit was 
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recently observed in colorectal cancer [165], where lower SDHB expression in 
human colorectal cancer tissues was reported. It was demonstrated that restoration of 
SDHB expression inhibited cancer growth both in vitro and in vivo.  
In summary, FXN aids in the synthesis of ISC which could account for the 
increasing abundance of SDHB, a protein containing ISC. Over-expression of FXN 
may increase the availability of ISC, and lead to higher assimilation of ISC into 
SDHB during protein synthesis. High SDHB level in turn promotes dehydrogenation 
of succinate to lower the level of succinate inside the cell. This relieves the negative 
regulation on PHDs, thereby promoting the degradation of HIF-1α through PHDs. 
This explains the changes of SDHB and HIF-1α levels observed in FXN OE cells. 
5.3.2 Lower intracellular ROS in OF cells could lower HIF-1α 
In section 4.2.3, over-expression of FXN was shown to lower intracellular 
ROS level. The effect of ROS in the regulation of HIF-1α and hypoxia is 
controversial. While some studies claim that ROS generated by the mitochondrial 
complex III can stabilize HIF-1α [166-168], it may well be due to ROS oxidization 
of the non-heme iron center within PHDs, which inhibits PHD activity, leaving  
HIF-1α to accumulate, instead of active HIF-1α induction. In support of this, more 
recent evidence proposed that HIF-1α stabilization may be independent of ROS 
generated from complex III of the mitochondria [169]. 
In the context of findings presented herein, the reduction in ROS level upon 
FXN OE was not a result of diminished mitochondrial function, since OXPHOS was 
higher in OF cells. Instead, lower intracellular ROS was due to higher ROS 
scavenging activity. Since drug-induced ROS production could induce stabilization 
of HIF-1α, it thus follows that ROS can regulate HIF-1α levels independently 
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without involvement of the mitochondria [170]. Over-expression of GPx1 on the 
other hand was also shown to suppress HIF-1α stabilization [171]. Therefore, lower 
intracellular ROS and higher GPx1 expression induced by FXN OE may both 
contribute to suppression of HIF-1α stabilization.  
The role of ROS in HIF-1α accumulation is still largely under debate [172, 
173], yet it is undeniable that ROS generation and detoxification play important 
roles in regulation of tumorigenesis and cancer metabolism [174]. 
5.3.3 Reduced EMMPRIN could induce metabolic changes in FXN OE 
In normal cells, glycolysis without ATP production through the ETC is 
energetically inefficient. Cancer cells on the other hand are reported to rely heavily 
on glycolytic ATP generation, even in the presence of oxygen [175].  One of the 
models explaining this phenomenon is the need to provide essential biosynthetic 
materials for rapid cell division [23].  
Glycolysis is interconnected with several metabolic pathways, and  
glycolytic intermediates are precursors for amino acid, nucleic acid and lipid 
synthesis. The pentose phosphate shunt, on the other hand, also provides the 
essential reducing equivalents in the form of NADPH, required for many 
biochemical reactions in the cell [23, 176]. Large amount of lactate produced at the 
end of glycolysis are eventually secreted, which may also benefit the tumor cells by 
inhibiting immune response in the surrounding environment [177, 178]. Acidic 
tumor microenvironment is also associated with increased metastasis and invasion 
[179, 180]. Lactic acid is mainly transported by monocarboxylate transporter (MCT) 
1 and 4 [181], which require EMMPRIN for proper function. EMMPRIN interacts 
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with MCT1/4, and act as a chaperone to promote MCT1/4 translocation and 
distribution to the plasma membrane.  
Reported to be up-regulate by HIF-1α during hypoxia [182], EMMPRIN is a 
transmembrane glycoprotein that is usually over-expressed in the tumor cells [183]. 
EMMPRIN induces matrix metalloproteinase production from nearby stromal 
fibroblast, and is involved in tumor-stroma cell interaction and metastatic 
progression [184-186]. Increased level of EMMPRIN is highly correlated with 
increased tumor progression [187-189] and lower survival rate [190-192] in various 
cancers including colorectal cancer. EMMPRIN expression is critical for tumor cells 
to maintain malignancy and tumor progression and is also reported to promote 
glycolysis in cancer cells [182, 193].  
Lower EMMPRIN expression is associated with numerous benefits. 
Silencing of EMMRIN inhibits glycolysis and lactate secretion, thereby leading to 
decreased cell proliferation, vascular endothelial growth factor production, 
invasiveness and tumorigenicity [193, 194]. Blocking EMMPRIN function with 
specific antibodies similarly down-regulated glycolysis and quickly induced cell 
death in colorectal cancer cells [195]. 
Given the intricate role of EMMPRIN in glucose metabolism and cancer, the 
reduced protein level of EMMPRIN in FXN OE cells may potentially be one of the 
key proteins potentiating the anti-tumor effect as a result of FXN over-expression 
and lower HIF-1α levels. 
5.3.4 Destabilization of HIF-1α explains the effect of FXN OE 
Under normoxia, PHDs catalyze the hydroxylation of proline residues on 
HIF-1α, which are signals for von Hippel-Lindau (VHL) binding, to target HIF-1α 
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for degradation. HIF-1α can be stabilized when PHDs are inhibited by hypoxia, 
succinate or ROS.  HIF-1α then dimerizes with HIF-1β, to cause activation of genes 
associated with the metabolic switch such as promoting glycolysis and inhibiting 
mitochondrial ATP production (Fig 5-5).  
 
Figure 5-5: Function and regulation of HIF-1α. HIF-1α levels depend on the activity of 
PHDs, which can be inhibited by hypoxia, succinate and potentially ROS. The stabilization 
of HIF-1α leads to hypoxia adaptation and a metabolic switch to favour glycolysis [196].  
 
Inhibition on PHDs may be relieved by lower succinate and ROS levels in 
OF cells, leading to higher degradation of HIF-1α. Increased OXPHOS observed in 
OF cells could thus be one intermediate effect of lower HIF-1α, a sign of reversed 
Warburg effect. Decreased HIF-1α may also be responsible for lower proliferation 
rate in OF from the inhibition of cell cycle. A study had shown HIF-1α depletion 
could induce p21 and p27 mRNA and protein levels, resulting in higher number of 
cells in G1 phase [197]. In this thesis, similar findings were demonstrated in FXN 
over-expression. The direct effect of lower HIF-1α was presented as a reduction of 



























Chapter 6: Conclusion and Future studies 
  




Figure 6-1: Flowchart depicting overall effect of FXN over-expression in cancer cells. 
Many key changes observed in FXN over-expressions resulted in decreased HIF-1α, an 
important regulator of metabolic switch in altering cancer cell metabolism. 
  
In this study, the anti-tumor effect of FXN over-expression in HCT116 was 
investigated. It was found that OF cells had a reduction in cell proliferation due to 
cell cycle inhibition by p21 and p27. This likely was the result of lower HIF-1α 
levels. The reduction of HIF-1α could be due to a combination of decreased 
succinate levels due to alteration of TCA cycle protein levels and changes in the 
redox status in the cell due to higher antioxidant enzymes, promoting the activity of 
PHDs. Other effects of HIF-1α in OF cells were the shift of metabolism by 
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6.2 Future studies 
6.2.1 Validation of HIF-1α induced effect in OF cells  
Based on this study, FXN OE lowers HIF-1α level. In the next stage of 
investigation, the effect of HIF-1α induction during hypoxic stress should be studied. 
This should involve assessing cell survival and HIF-1α protein level, as well as 
measuring the abundance of targets downstream of HIF-1α by using targeted 
proteomics and functional assays. Some of these candidates should include GLUT1, 
which is involved in uptake of glucose into the cell [33]; monocarboxylate transport 
4 (MCT4), which is associated with EMMPRIN and involved in removal of lactate 
from the cells [37]; as well as pyruvate dehydrogenase kinase (PDK), that 
phosphorylates and inactivates pyruvate dehydrogenase (PDH) catalyzing the 
conversion of pyruvate to acetyl-coA [39]. All these HIF-1α regulated genes are 
important nodes in the cancer metabolic switch. 
6.2.2 Measurement of succinate levels in OF cells 
Protein level of SDHB was found to be increased in OF cells and could 
potentially reduce the level of succinate, that in turn regulates the activity of PHDs. 
To fully substantiate this claim, succinate level should be measured directly in OF 
and CAT cells. This would further strengthen the linkage between FXN, oxidative 
phosphorylation and HIF-1α levels.  
6.2.3 Measurement of iron level and the effect of iron chelation on OF cells 
Iron is an essential element required for life [198]. The importance of iron in 
cell metabolism is highlighted by its presence in numerous crucial enzymes such as 
those in the cytochrome p450 family, ribonucleotide reductase and prolyl 
hydroxylase, which perform critical functions in regulating cell growth, metabolism 
  90  
  
and hypoxia [199, 200]. However, free iron is highly toxic to cells due to its redox 
properties. Without protective mechanisms in place, iron can catalyze detrimental 
production of ROS [201]. 
Mitochondria are key organelles involved in the synthesis of ISC and heme, 
and involved in cellular iron storage [202, 203]. Previous works have suggested that 
FXN may act as a sensor of intracellular iron level, as well as regulate iron 
metabolism in the mitochondria [204]. FXN also binds iron and may act as an iron 
chaperone that releases iron during ISC biosynthesis (Fig 6-2).   
 
Figure 6-2: Possible function of FXN. Frataxin may act as a A) iron storage protein similar 
to ferritin. B) An iron chaperone protein by bind to iron and delivering it to heme and ISC 
synthesis. C) A negative regulator of ISC synthesis during high iron level to limit ISC over-
production. D) As a metabolic switch between ISC and heme synthesis. Figure reproduced 
from Richardson et al. [205]. Copyright © 2010 PNAS 
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It is also postulated that FXN may function as a mitochondrial iron storage 
protein by assembling into oligomers that possess ferroxidase activity, catalysing 
Fe2+ to Fe3+ and sequestering these ions in a higher order complex. This prevents the 
iron from taking part in unwanted redox reactions [206]. However, these studies 
were done on yeast and bacteria homologue and evidence have been lacking in 
human FXN. 
Association of iron metabolism and cancer has been reported in cell lines as 
well as animal models [207]. A clinical trial evaluated the efficacy of iron chelator 
with radiotherapy in pancreatic cancer showed promising result [208]. Regulation of 
iron metabolism can further affect HIF-1α levels as PHDs that cause HIF-1α 
degradation are also iron-dependent enzymes. PHDs can be inhibited if intracellular 
iron levels are low, resulting in stabilization of HIF-1α. Given the intricate link 
between iron metabolism, FXN and hypoxia, it is intuitive to further investigate 
level of free and bound iron, as well as the effect of iron chelation in FXN OE cells. 
Measurement of labile iron pool in CAT and OF cells -  The labile iron 
pool (LIP) is a chelatable and redox-active iron pool in the cell [209] that must be 
tightly regulated to restrict the oxidative damage induced by Fenton chemistry [210]. 
LIP is dynamic and its level is representative of total iron level in the cell and its 
regulation [211]. In order to determine if the over-expression of FXN indeed affects 
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Effect of iron chelation on FXN OE cells – Treatment with membrane-
permeable iron chelator Dp44mt inhibits proliferation. At 35nM concentration, 
Dp44mt causes a 50% reduction in wild type HCT116 proliferation after 48 hours 
(Fig 6-3). Using these parameters, the following should be investigated: (i) whether 
FXN OE affects the efficacy of Dp44mt treatment, as well as (ii) whether Dp44mt 
treatment modulates cell cycle of OF cells. 
 
 
Figure 6-3: Dp44mt inhibits proliferation of HCT116. HCT116 cells were treated with 
increasing concentration of Dp44mt, an iron chelator for 48 hours. The number of cells 
remaining at each concentration was expressed as a percentage of the untreated control. IC50 
of Dp44mt at 48hr is approximately 35nM.   






















Chapter 7: Materials and methods 
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7.1 Cell lines and constructs 
7.1.1 HCT116 cell line and cell culture 
Human Colorectal Carcinoma Cell Line HCT116 was purchased from 
American Type Culture Collection (ATCC; Manassas, VA). HCT116 was cultured 
in McCoy’s 5A media [modified] with L-glutamine (Sigma Aldrich, St Louis, MO) 
supplemented with 7.5% (w/v) sodium bicarbonate (Sigma Aldrich),  10% fetal 
bovine serum  (Gibco, Life Technologies, Carlsbad, CA)  and 1% 
antibiotic/antimycotic (Life Technologies), in a humidified incubator at 37 °C in 5% 
(v/v) CO2. Culture reached sub-confluency every 2-3 days and was sub-cultured. 
7.1.2 Transfection 
Plasmid vector containing Frataxin gene (a gift from Dr. Bi Xuezhi), was 
constructed using Vivid Colors™ pcDNA™ 6.2 / EmGFP-Bsd / V5-DEST 
Mammalian Expression Vector (Life Technologies). Control plasmid containing 
Chloramphenicol acetyltransferase (CAT) gene was provided with the kit. 
Transfection of FXN-V5 and CAT control into HCT116 was carried out using 
electroporation (Cell Line Nucleofector® Kit V, Amaxa Biosystem) according to 
manufacturer’s protocol.  
7.1.3 Determination of blasticidin sensitivity 
35,000 wild-type HCT116 cells were seeded in 24-well plates for 24 h. The 
cells were treated with McCoy’s 5A medium containing 0 μg/ml, 5 μg/ml, 7.5 μg/ml, 
10 μg/ml and 12.5 μg/ml of blasticidin (Life Technologies). After 72 h, the 
minimum concentration of blasticidin which inhibited the growth of normal 
HCT116 was determined. 
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7.1.4 Stable cell line selection 
After transfection, cells were diluted in McCoy’s 5A media containing 7.5 
μg/ml blasticidin. Transfected cells were sparsely seeded with the ratio of 1:20 in 60 
mm plates to allow colony amplification from single cells over a period of 5 – 7 
days. Visible colonies were trypsinized individually and re-cultured in each well of a 
24-well plate. Eventually six colonies showed healthy growth and were expanded 
and screened using V5 antibodies to check for FXN over-expression. 
7.1.5 Preparation of whole cell lysate 
Cells were trypsinized and spun down at 500 g for 5min. The supernatant 
was removed and the cell pellets were washed thrice with 1× Phosphate Buffered 
Saline (PBS). The cells were lysed using RIPA buffer (1% Sodium Deoxycholate, 
0.1% SDS, 1% Triton X -100, 0.01 M Tris-HCL pH 8.0, 0.14 M NaCl) with 1× 
HaltTM  protease inhibitor cocktail, EDTA free (Pierce). After a brief vortex, lysates 
were centrifuged at 14,500 g at 4 oC for 20 min, and the supernatant was aspirated 
into a clean tube.  Protein concentrations were determined using Coomassie Plus 
Protein Assay Reagent kit (Pierce) with modifications. Proteins were then stored at 
−80 oC. 
7.2 Cell based assays 
7.2.1 Crystal Violet staining 
Each well was washed twice with PBS. Adherent cells were incubated with 
0.5% crystal violet in 20% methanol for 10 min, and each well was washed with 
PBS to remove residual crystal violet stain. The plate was left to dry overnight, and 
cells stained with crystal violet were solubilized using 500 μl of 1% SDS for 15  min. 
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Absorbance was read at 520 nm by a spectrometer (Infinite M200, TECAN, 
Männedorf, Switzerland). 
7.2.2 Proliferation assay 
Cells were seeded at 2,000 cells per well, in triplicates, in four 96-well plates. 
Every 24 h, one plate was removed and proliferation was terminated. After washing 
the cells with PBS, the amount of cells was quantified by crystal violet staining. Cell 
proliferation was followed over a course of 96 h. 
7.2.3 TBHP treatment 
For TBHP survival assay, 35,000 cells were seeded in triplicate in 24-well 
plates. Cells were treated with 0 μM, 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM 
and 70 μM TBHP (Sigma Aldrich) 24 h after seeding and cultured for another 24 h.  
Adherent cells were quantified using crystal violet staining. 
7.3 Flow cytometry 
Flow cytometry was performed on FacsAria II (BD Biosciences, San Jose, 
CA) and data collected using FACS Diva v6 software (BD Biosciences). Cells were 
fixed by adding −20 °C 100% ethanol dropwise with shaking to a cell suspension in 
1 ml PBS to a final concentration of 70% ethanol.  
7.3.1 Cell cycle analysis 
250,000 cells were seeded in 6 well plates for 48 h before harvesting. It was 
ensured that the cells had not reached more than 90% confluency. Collected cells 
were washed twice with ice-cold PBS before fixing with 70% ethanol at −20 oC 
overnight. After fixing, cells were washed twice with PBS and incubated with 50 
µg/mL PI, 50 ug/mL RNase in PBS for 3 h before flow cytometry analysis. Data 
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from 20,000 singlets were recorded. Analysis of cell cycle was carried out using 
ModFIT LT software version 3.3 (Verity Software House Inc., Topsham, ME). 
7.3.2 Mitochondrial membrane potential measurement 
250,000 cells were seeded in 6 well plates for 48 h, before being harvested, 
fixed in 70% cold ethanol and stained using the JC10 mitochondrial membrane 
potential assay kit (Abcam). Data from 10,000 singlets were recorded and analysis 
was carried out using Cyflogic version 1.2.1 (CyFlo Ltd) 
7.3.3 ROS measurement 
250,000 cells were seeded in 6 well plates for 48 h. After 48 h, cells were 
loaded with 5 mM 2’,7’Dichloro-dihydro-fluorescein diacetate (DCFH, Life 
Technologies) in growth media for 30 min before the cells were harvested, washed 
and fixed for 30 min and analyzed using FACS. Data from 10,000 singlets were 
recorded. Data analysis was carried out using Cyflogic version 1.2.1 (CyFlo Ltd, 
Turku, Finland).  
7.4 iTRAQ proteome profiling 
7.4.1 iTRAQ labeling chemistry 
Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) uses up to 
four or eight different isobaric labels for relative quantification of protein expression. 
The technology lies in the design of the isobaric labels (Fig 7-1), where each label 
consists of a reporter group, balance group and a peptide reactive group. In four-plex 
iTRAQ, the reporter groups have masses of 114, 115, 116 and 117, however the 
overall mass of each label is kept constant by balancing it with a neutral loss group. 
During chemical labeling, the peptide reactive groups link covalently with lysine 
side chain amine groups as well as the N-termini of all peptides, ensuring complete 
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coverage of the entire proteome. As each iTRAQ label adds the same mass to every 
peptide, peptide precursors from different samples would still appear as a single 
peak in MS. During fragmentation, the reporter group is released along with the 
usual fragmentation of peptides. The intensity of the reporter indicates the relative 
abundance of that peptide in each sample and the MS/MS spectra of the peptides 
identify the peptide sequence.  
 
Figure 7-1: Chemistry of the iTRAQ Label. Equal mass of each label is maintained with 
neutral loss of the balance group. This ensures the same peptide with different label would 
only appear as a single peak in MS. The reporter group quantifies peptides from respective 
sample in MS/MS. 
 
7.4.2 Protein extraction for iTRAQ 
Control and OF  cells were harvested and lysed with 500 mM 
triethylammonium bicarbonate (TEAB; Sigma), 1.0% (w/v) SDS and boiled at 100 
oC for 10 min. Supernatant was retained after centrifugation at 14,500g for 30 min at 
4°C. Estimation of protein content was carried out using RC-DC protein assay kit 
(Bio-Rad, Hercules, CA). 
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7.4.3 iTRAQ labeling and sample preparation 
100 μg of each sample was reduced with tris-(2-carboxyethyl) phosphine 
(TCEP) and alkylated with methyl methane-thiosulfonate (MMTS). After cysteine 
blocking, the samples were trypsinized for 16 h at 37°C. After digestion, each 
sample was dried and reconstituted with 0.5M TEAB. Each digested sample was 
labeled for 2 h at room temperature with one of the four isobaric amine-reactive tags, 
114 for CAT control and 115, 116, 117 for OE cells OF1, OF5 and OF6 respectively. 
The four iTRAQ-derivatized samples were then pooled and passed through a strong 
cation exchange cartridge following manufacturer’s protocol (Applied Biosystems, 
Foster City, CA) to remove interfering substance such as excess iTRAQ regents, 
organic solvent and SDS. The samples after clean-up were desalted using a C-18 
Sep-Pak cartridge (Merck Millipore) and lyophilized, before reconstitution in 95% 
H2O, 5% acetonitrile (ACN) and 0.1% formic acid (FA) for 2D-LC separation. 
7.4.4 2D-LC separation 
The first dimension peptide separation was performed using the Ultimate LC 
system (Dionex-LC-Packings, Sunnyvale, CA) connected to a strong cation-
exchange (SCX) column. Ninety-six microgram (via multiple injections) of the 
labeled peptide mixture was injected using the micro-pickup mode into a Zorbax 
Bio-SCX II column (Agilent, SantaClara, CA). SCX mobile phase A was 5% ACN 
and 0.05% FA and mobile phase B was 5% ACN, 500 mM NaCl and 0.05% FA. 
The flow rate was set at 10µl/min. A total of 43 fractions were eluted (2 min each) 
and collected on a 96 well v-bottom plates using step gradients of mobile B as 
follows: 5% for 1 min, 5-12% for next 29 min, 12-30% for next 90 min, 30-90% for 
next 2 min, hold at 90% for next 7 min and 90-5% for last 5 min and continued at 5% 
for another 12 min. The eluted fractions were subsequently combined to 9 fractions 
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and then desalted with Sep-Pak® tC18 µElution Plate (186002318, Waters Corp., 
Milford, MA) using a vacuum manifold (Merck Millipore) in accordance to the 
manufacturer’s recommendations, before second-dimension reversed-phase (RP) 
chromatography. From RP separation of each fraction, 5 µg was trapped on a pre-
column (200 µm x 0.5 mm) and then eluted on an analytical column (75 µm x 150 
mm). Both columns were packed with Reprosil-Pur C18-AQ 3 µm 120 Å phase 
(Eksigent, Dublin, CA). The RP mobile phase A was 98% H2O (with 0.1% FA) 
while RP mobile phase B was 98% ACN (with 0.1% FA). The peptides were 
separated by a linear gradient of 12-30% of mobile B in 90 min at a flow rate of 300 
nl/min. 
7.4.5 Tandem mass spectrometry 
The tandem MS analysis was performed using a 5600 TripleTOF analyzer 
(QqTOF; AB SCIEX, Framingham, MA) in Information Dependent Mode. 
Precursor ions were selected across the mass range of 400-1800 m/z using 250 ms 
accumulation time per spectrum. A maximum of 20 precursors per cycle from each 
MS spectra were selected for MS/MS analyses with 100 ms accumulation time for 
each precursor and dynamic exclusion for 15 s. Tandem mass spectrometry was 
recorded in high sensitivity mode with rolling collision energy on and iTRAQ 
reagent collision energy adjustment on. 
Precursor ions were selected across the mass range of 350-1250 m/z using 250 ms 
accumulation time per spectrum. A maximum of 20 precursors per cycle from each 
MS spectra were selected for MS/MS analyses with 100 ms accumulation time for 
each precursor and dynamic exclusion for 8 s. Tandem mass spectrometry was 
recorded in high sensitivity mode with rolling collision energy on. 
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7.4.6 Peptide and protein identification 
Protein identification and relative iTRAQ quantification were performed 
with ProteinPilot™ Software 4.1 (AB SCIEX) using the Paragon™ algorithm for 
the peptide identification, which was further processed by Pro Group™ algorithm 
where isoform-specific quantification was adopted to trace the differences between 
expressions of various isoforms. The Pro Group Algorithm calculates protein ratios 
using only ratios from the spectra that are distinct to each protein or protein form 
and thus eliminates any masking of changes in expression because of peptides that 
are shared between proteins. User defined search parameters were as follows: (1) 
Sample Type: iTRAQ 4 plex (Peptide Labeled); (2) Cysteine Alkylation: MMTS; (3) 
Digestion: Trypsin; (4) Instrument: TripleTOF5600; (5) Special Factors: None; (6) 
Species: Homo sapiens; (7) ID Focus: Biological modifications; (8) Database: 
ipi.HUMAN.v3.87.fasta (182888 proteins searched); (9) Search Effort: Thorough; 
(10) the False Discovery Rate Analysis: Yes; (11) User Modified Parameter Files: 
Yes. For iTRAQ quantitation, the peptide for quantification was automatically 
selected by Pro Group™ algorithm to calculate the reporter peak area, error factor 
(EF) and p-value. The resulting data set was auto bias-corrected to remove any 
variations resulting from unequal mixing when combining labeled samples. Each 
modified peptide was counted as a unique peptide. The peak areas and the signal-to-
noise (S/N) ratios were extracted from the database by Protein Pilot to process the 
raw data for quantification. A reverse database search strategy was adopted to 
estimate the false discovery rate for peptide identification. A strict unused score 
above 1.3 was used as the qualification criteria, which corresponds to a peptide 
confidence level of 95%. With this filter, the corresponding false discovery rate of 0% 
was calculated from the decoy hits. 
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7.4.7 Protein annotation, data representation and enrichment analysis 
For determination of consistency within biological triplicates, log ratio of all 
peptides from OF1, OF5 and OF6 were plotted pair wise and their r-square values 
were calculated with MS EXCEL.  Coefficient of variation for proteins with 
differential abundance was calculated using MS EXCEL. Proteins with differential 
abundance were annotated using UniprotKB Protein Knowledgebase 
(http://www.uniprot.org/). The proteins were classified based on Uniprot keywords 
under the category of Biological process. Significantly altered protein list was 
uploaded into Database for Annotation, Visualization and Intergrated Discovery 
(DAVID v6.7, http://david.abcc.ncifcrf.gov) for functional annotation and 
enrichment analysis [212, 213]. Enriched targets were mapped onto KEGG pathway 
using the Functional Annotation Tool. 
7.5 SWATH™ MS proteome profiling 
7.5.1 Protein extraction and sample preparation 
Control and OF cells were harvested and lysed in 8M Urea, 25mM TEAB, 2% 
Triton X-100, 0.1% SDS supplemented with 1× HALT protease inhibitor cocktail 
(Thermo scientific), 50 µg/ml DNase I (Sigma) and 50 µg/ml RNase A (Sigma). 
Supernatant was acquired after centrifugation at 14,500g for 30 min at 15°C. Protein 
estimation was carried out using RC-DC protein assay kit (Bio-Rad, Hercules, CA).  
7.5.2 LC separation 
Four microgram of each sample was separated on the same RP LC setup 
(Section 7.4.4, second dimension separation). Mobile phase A: 0.1% FA in 2% ACN. 
Mobile phase B: 0.1% FA in 98% ACN. Flow rate was set to 300 nL/min. LC 
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gradient: 1 min of 95% A, 29 min of 95-88% A, 90 min of 88-70% A, 2 min of 70-
10% A, 7 min of 10% A, 3 min of 10-95% and 14 min of 95% A. 
7.5.3 SWATH™ acquisition mass spectrometry 
Samples were analyzed on a TripleTOF 5600® system (QqTOF; AB SCIEX,) 
in SWATH mode. Each acquisition method had a cycle time of 3 s, consisting of 36 
acquisition window of 25 Da, each with 80 ms accumulation time and 50 ms of 
TOF/MS survey scan from 350 to 1250 Da. Each MS/MS acquisition window 
consisted of a scan of 100 to 1,800 Da and was performed using collision energy of 
35 V with a spread of 15 V. 
7.5.4 SWATH™ ion library generation 
An ion library was generated using a pool of all samples in equal proportion 
that was separated using the same LC gradient (Section 7.5.2) and analyzed on a 
TripleTOF 5600® system (QqTOF; AB SCIEX,) in Information Dependent Mode. 
Precursor ions were selected across the mass range of 350-1250 m/z using 250 ms 
accumulation time per spectrum. A maximum of 20 precursors per cycle from each 
MS spectra were selected for MS/MS analyses with 100 ms accumulation time for 
each precursor and dynamic exclusion for 8 s. Tandem mass spectrometry was 
recorded across the mass range of 100-1800 m/z in high sensitivity mode with 
rolling collision energy on. 
7.5.5 Protein identification and quantitation 
Protein identification was performed with ProteinPilot™ Software 4.1 (AB 
SCIEX) as previously described (Section 7.4.6). User defined search parameters 
were as follows: (1) Sample Type: Identification; (2) Cysteine Alkylation: MMTS; 
(3) Digestion: Trypsin; (4) Instrument: TripleTOF5600; (5) Special Factors: None; 
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(6) Species: Homo sapiens; (7) ID Focus: Biological modifications; (8) Database: 
ipi.HUMAN.v3.87.fasta (182888 proteins searched); (9) Search Effort: Thorough; 
(10) the False Discovery Rate Analysis: Yes; (11) User Modified Parameter Files: 
No. The proteins identified were used to generate an ion library for SWATH™. 
Peak alignment and data interrogation was done using PeakView software 
V1.2.0.3(AB SCIEX) supplement with MS/MS(ALL) with SWATH Acquisition 
Microapp, version 1.0.0.653 add-on with the following filter: Peptide confidence: 
99%, Exclude modifications: Yes, Exclude Shared: Yes. 
7.6 Metabolomics profiling 
7.6.1 Metabolite extraction 
Metabolites were extracted from control and OF cells using 80% methanol. 
Cells from OF1, 5, 6 and CAT were seeded in 15 mm dish and grown to 70% 
confluency. Cells were lysed by adding -80°C 80% methanol and scraped down. 
Cell debris was pelleted at 16,000 g for 10 min at 4°C and the supernatants were 
retained for LC-MS analyses. To obtain similar concentration of metabolites within 
samples, the amount of 80% methanol used was 1 mL per 106 cells. Cell numbers 
were determined using a counting plate, seeded alongside the triplicate plates. 
7.6.2 LC separation 
10 µl of extracted metabolite samples were separated on Agilent1290 
Infinity LC (Agilent, Santa Clara, CA) with Phenomenex (Torrance, CA) Kinetex 
HILIC column (2.6 µm ID x 5 cm). Mobile phase A: H2O with 0.1% FA. Mobile 
phase B: ACN with 0.1% FA. Flow rate is set at 0.3 mL/min. LC gradient: 5 min of 
5% A, 19 min of 5-50% A, 4 min of 50-80% A, 2 min of 80% A, 1 min of 80%-20% 
A, 8 min of 20% A.  
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7.6.3 Tandem mass spectrometry 
Samples were analyzed on a TripleTOF 5600 system (QqTOF; AB SCIEX) 
in an Information Dependent Acquisition (IDA) LC/MS/MS method. Each IDA 
method consisted of a high-resolution TOF/MS survey scan of 50-1000 m/z mass 
range for 100 ms accumulation time, followed by the selection of up to 20 singly-
charged precursors for MS/MS analyses. Each MS/MS acquisition was performed 
using rolling collision energy and acquired for 100 ms. Dynamic exclusion for 3 s 
was performed.  
7.6.4 Metabolite quantitation and identification 
Data processing and interpretation were performed using PeakView software (AB 
SCIEX). Peak alignment and peak area integration was performed with MultiQuant 
software (AB SCIEX). Triplicate runs from OF1, OF5 and OF6 were averaged. 
Triplicate runs from CAT were averaged. Comparison was done within all OF 
samples versus CAT samples. Differential peaks with fold change ≥1.5 and p value 
< 0.05 were selected for peak identification. For metabolite identification, MS and 
MS/MS spectra of each peak was searched using MS/MS spectrum Match tool 
(http://metlin.scripps.edu/spec_search.php) available from the METLIN database 
(http://metlin.scripps.edu/index.php). 
7.6.5 Data representation 
For visualization of data, metabolite dataset were uploaded to XCMS online 
(https://xcmsonline.scripps.edu/), a web-based metabolomics data processing 
platform. XCMS performs feature detection, which are peaks with retention time 
corrected and aligned across all dataset. Using these features, XCMS then annotates, 
quantifies and performs statistical analyses. XCMS online also generates 
visualization plot of the data, providing a clearer picture of the metabolic differences 
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between CAT and OF156. A comparison analysis was carried out with predefined 
settings with the closest match of the instrumentation used. MarkerView™ software 
was used for quantitation of the metabolomics data. MarkerView™ also performs 
peak detection, retention time alignment as well as quantitation. Importantly, 
MarkerView™ also offers various methods for data normalization during 
quantification providing a more reliable relative abundance of metabolites. 
7.7 Molecular methods 
7.7.1 Western blot 
Twenty microgram of whole cell lysate (Section 7.1.5) was separated with 
12.5% SDS-PAGE. Proteins were electroblotted onto PVDF membrane (Bio-Rad) at 
50V for one hour at 4 oC. Blocking and subsequent antibody incubation were 
performed with 5% and 1% non-fat milk in PBS with 0.05% Tween-20 respectively. 
The primary antibodies used were anti-FXN (Merck Millipore, Billerica, MA), anti-
V5, (Life Technologies), cyclin D and cyclin E (Cell Signaling Technology, 
Danvers, MA), p21, p27, cdk2, cdk4, EMMPRIN, HIF-1α (Santa Cruz, Dallas, TX), 
GPx1, ATP5O (Abcam, Cambridge, UK) and actin (GE Healthcare, 
Buckinghamshire, UK). The secondary antibodies used were anti-mouse antibody 
conjugated with HRP (BD biosciences), anti-goat antibody conjugated with HRP 
(Thermo scientific) and anti-rabbit antibody conjugated with HRP (GE Healthcare).   
7.7.2 Reverse transcriptase PCR 
Total RNA was isolated from control and FXN over-expressing cell using 
RNeasy Plus minikit (Qiagen, Chatworth, CA) according to manufacturer’s protocol. 
SuperScript® III kit was used to perform a two step reverse transcription PCR on 
the isolated RNA using the following primers: FXN forward primer 5'-
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GCCTCAACCAGATTTGGAAT-3', FXN reverse primer 5'-
CTGGACTTGTCTTCCTTGGC-3' or V5 Reverse primer 5'-
ATCCCTAACCCTCTCCTCGGT-3'. Negative control for presence of genomic 
DNA was carried out without reverse transcriptase in the reaction mix. 
7.8 Statistical analysis 
All experiments were carried out in triplicate unless stated otherwise. 
Student’s t-test was performed using GraphPad Prism Version 5 (GraphPad 
Software, Inc., La Jolla, CA). 
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Appendix I: Metabolites with altered concentrations in OF cells. 
Compound m/z Retention time in mins Fold change# p-value
5′-Deoxy-5′-(methylthio)adenosine 298.0976 18.66 2.698 0.0169
Butenoyl PAF 550.386 12.18 2.521 0.00988
L-Carnitine 162.1117 10.47 2.319 0.00057
PC(16:0/0:0)[U] / PC(16:0/0:0)[rac] 496.3382 12.45 2.268 0.00616
PAF C-16 546.3554 12.29 2.236 0.01294
Thr Cys Gly 280.0903 16.57 2.191 0.01818
Choline 104.1054 11.42 2.024 6.4249E-05
Phosphocholine 184.0733 16.58 1.963 0.00391
Glutathione, oxidized 613.161 14.54 1.825 0.01129
Glycerophosphocholine 292.0726 16.58 1.771 0.01234
Lyso-PAF C-16 482.3602 12.65 1.755 0.00068
L-Arginine 175.1183 15.95 1.704 0.0001
Elaidylphosphocholine 434.3402 12.64 1.610 0.00712
D-Lysine 147.1118 15.93 1.599 0.00031
L-Methionine S-oxide 166.0524 12.6 1.537 6.4764E-06
3-Methyl-L-histidine 170.0899 16.67 1.462 0.0111
L-Valine 118.085 9.49 1.412 9.1302E-07
L-Tyrosine 182.0802 9.2 1.387 0.03751
L-Methionine 150.0579 9.42 1.348 5.9789E-06
(R)-(+)-2-Pyrrolidone-5-carboxylic acid 130.05 11.15 1.299 0.00021
Betaine 118.0856 11.87 1.277 5.8829E-05
  
     
  
109 
Compound m/z Retention time in mins Fold change# p-value
L-proline 116.0696 10.78 1.209 0.00026
D-Glutamine 145.0618 11.1 1.195 0.0425
L-Phenylalanine 166.0853 8.89 1.174 0.00589
Creatine 130.0622 9.73 1.067 0.00805
L-Asparagine 131.045 10.83 -1.079 0.04898
cGMP 366.0153 9.93 -1.094 0.01684
Isobutyryl carnitine 232.1538 8.79 -1.124 0.03287
Trans-4-Hydroxy-L-proline 130.0503 10.8 -1.148 0.03602
Dihomo-γ-Linolenoyl PAF C-16 792.5896 10.7 -1.184 0.00182
Glutathione 306.076 10.15 -1.242 0.00026
Eicosapentaenoyl PAF C-16 766.5669 10.77 -1.252 0.0067
L-Glutamate 146.0451 9.54 -1.261 5.3322E-05
PC(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)) 778.5375 10.82 -1.314 0.00297
SM(d18:1/16:0) 725.5591 11.84 -1.330 0.00025
Acetylcarnitine 204.1212 9.76 -1.467 0.03115
1-Octadecyl Lysophosphatidic Acid 425.3102 11.5 -1.646 0.00095
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Appendix II: Altered proteins in FXN OE as identified by iTRAQ 
Accession 
No. Gene name Protein name Peptides 
Fold change# 
(±S.D.) 
IPI00925572 ASNS  Asparagine synthetase [glutamine-hydrolyzing] isoform b 4 3.971 ± 0.794 
IPI00425562 SCRIB  Isoform 2 of Protein scribble homolog 3 3.033 ± 0.345 
IPI00335069 PSMD12  26S proteasome non-ATPase regulatory subunit 12 isoform 2 2 3.007 ± 0.217 
IPI00900380 MCTS1  Isoform 2 of Malignant T cell-amplified sequence 1 2 2.563 ± 0.284 
IPI00759832 YWHAB  Isoform Short of 14-3-3 protein beta/alpha 15 2.594 ± 0.316 
IPI00007811 CDK4  Cyclin-dependent kinase 4 2 2.146 ± 0.563 
IPI00289159 GLS  Glutaminase kidney isoform, mitochondrial 8 2.117 ± 0.388 
IPI00927799 CTNNB1  Beta-catenin 3 2.078 ± 0.435 
IPI00003704 RBM4  RNA-binding protein 4 10 2.298 ± 0.11 
IPI00019359 KRT9  Keratin, type I cytoskeletal 9 2 3.041 ± 0.839 
IPI00845507 RPL21  60S ribosomal protein L21 4 2.236 ± 0.599 
IPI01022431 ALDH2  Aldehyde dehydrogenase, mitochondrial 3 2.029 ± 0.436 
IPI00965445 FIP1L1  Pre-mRNA 3'-end-processing factor FIP1 3 2.514 ± 0.897 
IPI01013106 BAG2  BAG family molecular chaperone regulator 2 3 1.956 ± 0.328 
IPI00021258 ARFIP1  Isoform B of Arfaptin-1 2 1.827 ± 0.43 
IPI01010990 LGALS3BP  Galectin-3-binding protein 4 1.583 ± 0.451 
IPI00017339 SF3B4  Splicing factor 3B subunit 4 6 2.09 ± 0.208 
IPI00646689 TXNDC17  Thioredoxin domain-containing protein 17 3 1.882 ± 0.223 
IPI00890727 SPATA5  Isoform 2 of Spermatogenesis-associated protein 5 2 1.839 ± 0.225 
IPI00641157 CTSA  lysosomal protective protein isoform c precursor 2 1.846 ± 0.331 
IPI01009918 PRSS1  Trypsin-1 16 2.492 ± 0.884 
  




No. Gene name Protein name Peptides 
Fold change# 
(±S.D.) 
IPI00967716 Sep 11  Septin-11 4 1.965 ± 0.342 
IPI00549296 SAP30BP  SAP30-binding protein 2 2.095 ± 0.448 
IPI00954530 OCIAD1  OCIA domain-containing protein 1 isoform 4 7 2.241 ± 0.231 
IPI00329801 ANXA5  Annexin A5 9 1.767 ± 0.191 
IPI00956296 APOPT1  Kinesin light chain 1 3 2.126 ± 0.317 
IPI00797126 NACA  Nascent polypeptide-associated complex subunit alpha 5 1.74 ± 0.377 
IPI00007611 ATP5O  ATP synthase subunit O, mitochondrial 11 1.84 ± 0.118 
IPI00795751 RPL23  60S ribosomal protein L23 14 1.817 ± 0.134 
IPI00221093 RPS17  40S ribosomal protein S17 5 1.948 ± 0.085 
IPI00909812 B4DTS6  CD97 antigen 2 1.818 ± 0.078 
IPI00964364 EEF1E1  Eukaryotic translation elongation factor 1 epsilon-1 3 1.998 ± 0.407 
IPI00156689 VAT1  Synaptic vesicle membrane protein VAT-1 homolog 11 1.694 ± 0.185 
IPI00946558 ALDH5A1  Succinate-semialdehyde dehydrogenase, mitochondrial 2 1.717 ± 0.144 
IPI00922336 TBL1XR1  F-box-like/WD repeat protein TBL1XR1 3 2.01 ± 0.221 
IPI01015990 Sep 7  Septin-7 2 1.607 ± 0.215 
IPI00216691 PFN1  Profilin-1 17 1.991 ± 0.326 
IPI00024320 RBM3  RNA-binding protein 3 8 1.822 ± 0.102 
IPI01024943 CLASP1  CLIP-associating protein 1 2 1.852 ± 0.239 
IPI00182373 P4HA2  Prolyl 4-hydroxylase subunit alpha-2 2 1.723 ± 0.1 
IPI00021267 EPHA2  Ephrin type-A receptor 2 4 1.735 ± 0.264 
IPI00017469 SPR  Sepiapterin reductase 3 1.721 ± 0.271 
IPI00646762 NUDT5  ADP-sugar pyrophosphatase 8 1.854 ± 0.086 
IPI00845446 PDS5B  Isoform 2 of Sister chromatid cohesion protein PDS5 homolog B 5 1.629 ± 0.183 
IPI00009276 PROCR  Endothelial protein C receptor precursor 2 1.568 ± 0.207 
  




No. Gene name Protein name Peptides 
Fold change# 
(±S.D.) 
IPI00410026 LUC7L  Isoform 2 of Putative RNA-binding protein Luc7-like 1 5 1.753 ± 0.408 
IPI00746438 RPL11  Isoform 2 of 60S ribosomal protein L11 8 1.951 ± 0.314 
IPI00171665 NUP37  Nucleoporin Nup37 2 1.641 ± 0.124 
IPI00216044 RALY  RNA-binding protein Raly 9 1.684 ± 0.072 
IPI00021405 LMNA  soform A of Prelamin-A/C 90 1.825 ± 0.108 
IPI00464979 SUCLA2  Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial 3 1.714 ± 0.172 
IPI00472442 PSMA1  Isoform Long of Proteasome subunit alpha type-1 7 1.58 ± 0.146 
IPI00019912 HSD17B4  Peroxisomal multifunctional enzyme type 2 3 1.486 ± 0.198 
IPI00910593 CNN2  Calponin-2 2 2.005 ± 0.45 
IPI01026232 NAP1L1  Nucleosome assembly protein 1-like 1 9 1.741 ± 0.148 
IPI00293425 FXN  Frataxin, mitochondrial 3 1.781 ± 0.428 
IPI00978887 RAB11B  Ras-related protein Rab-11B 3 1.619 ± 0.12 
IPI00746165 WDR1  WD repeat-containing protein 1 5 1.637 ± 0.144 
IPI00909097 CIRBP  Cold-inducible RNA-binding protein 3 1.711 ± 0.129 
IPI00908949 TARS  Threonyl-tRNA synthetase, cytoplasmic 2 1.691 ± 0.04 
IPI00856098 RRBP1  p180/ribosome receptor 21 1.641 ± 0.09 
IPI00788849 TFG  Protein TFG isoform 2 6 1.716 ± 0.066 
IPI00294911 SDHB  Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 8 1.623 ± 0.174 
IPI01009326 CCT8  T-complex protein 1 subunit theta 25 1.602 ± 0.031 
IPI00930174 HIST2H2BF  Histone H2B type 2-F isoform b 46 1.72 ± 0.323 
IPI00021327 GRB2  Growth factor receptor-bound protein 2 2 1.517 ± 0.099 
IPI00515061 HIST1H2BJ  Histone H2B type 1-J 41 1.665 ± 0.15 
IPI00465151 RAB11FIP1  Isoform 2 of Rab11 family-interacting protein 1 3 1.613 ± 0.058 
IPI00014808 PAFAH1B3  Platelet-activating factor acetylhydrolase IB subunit gamma 3 1.747 ± 0.117 
  




No. Gene name Protein name Peptides 
Fold change# 
(±S.D.) 
IPI00942092 ADSL  Adenylosuccinate lyase 3 1.598 ± 0.189 
IPI00418497 TIMM50  Isoform 2 of Mitochondrial import inner membrane translocase subunit TIM50 3 1.793 ± 0.157 
IPI00946474 NDUFA5  NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 3 1.545 ± 0.121 
IPI00967869 CAMK2D  Calcium/calmodulin-dependent protein kinase type II subunit delta 3 1.651 ± 0.174 
IPI00017334 PHB  Prohibitin 25 1.574 ± 0.139 
IPI00941463 NAP1L4  Nucleosome assembly protein 1-like 4 7 1.69 ± 0.213 
IPI00010415 ACOT7  Cytosolic acyl coenzyme A thioester hydrolase 2 1.595 ± 0.027 
IPI00099996 RG9MTD1  Mitochondrial ribonuclease P protein 1 7 1.61 ± 0.091 
IPI00019755 GSTO1  Glutathione S-transferase omega-1 5 1.647 ± 0.261 
IPI00100748 HSPBP1  Hsp70-binding protein 1 2 1.634 ± 0.264 
IPI00647491 KIAA0391  Mitochondrial ribonuclease P protein 3 2 1.613 ± 0.056 
IPI00922214 RDBP  Negative elongation factor E 2 1.657 ± 0.399 
IPI00013683 TUBB3  Tubulin beta-3 chain 65 1.675 ± 0.223 
IPI01018641 SNRPB  Small nuclear ribonucleoprotein-associated proteins B 5 1.507 ± 0.083 
IPI00980165 MANF  Mesencephalic astrocyte-derived neurotrophic factor 6 1.54 ± 0.044 
IPI00011996 UBE2Z  Ubiquitin-conjugating enzyme E2 Z 2 1.639 ± 0.104 
IPI00647286 FAM129B  Niban-like protein 1 3 1.608 ± 0.125 
IPI00291467 SLC25A6  ADP/ATP translocase 3 4 1.597 ± 0.049 
IPI00440727 BRD4  Bromodomain-containing protein 4 3 1.61 ± 0.097 
IPI00024911 ERP29  Endoplasmic reticulum resident protein 29 8 1.48 ± 0.047 
IPI00021700 PCNA  Proliferating cell nuclear antigen 9 1.586 ± 0.08 
IPI00382869 FDPS  Farnesyl pyrophosphate synthetase like-4 protein (Fragment) 3 1.607 ± 0.091 
IPI00900366 KIAA0564  von Willebrand factor A domain-containing protein 8 3 1.507 ± 0.1 
IPI00910821 GPX8  Glutathione peroxidase 8 3 1.558 ± 0.078 
  




No. Gene name Protein name Peptides 
Fold change# 
(±S.D.) 
IPI00218606 RPS23  40S ribosomal protein S23 2 1.531 ± 0.051 
IPI00002134 PSMD5  26S proteasome non-ATPase regulatory subunit 5 2 1.424 ± 0.09 
IPI00890837 SMCHD1  Structural maintenance of chromosomes flexible hinge domain-containing protein 1 3 1.471 ± 0.051 
IPI00166749 PMPCA  Mitochondrial-processing peptidase subunit alpha 4 1.532 ± 0.047 
IPI00829819 C9orf80  Isoform 2 of SOSS complex subunit C 3 1.529 ± 0.158 
IPI00001639 KPNB1  Importin subunit beta-1 11 1.607 ± 0.102 
IPI00003217 PSMB7  Proteasome subunit beta type-7 5 1.472 ± 0.056 
IPI00216695 BAZ1B  Isoform 2 of Tyrosine-protein kinase BAZ1B 7 1.522 ± 0.108 
IPI00016342 RAB7A  Ras-related protein Rab-7a 6 1.438 ± 0.115 
IPI00021766 RTN4  Reticulon-4 5 1.508 ± 0.199 
IPI00001589 TIMM13  Mitochondrial import inner membrane translocase subunit Tim13 2 1.544 ± 0.246 
IPI00337494 SLC25A24  Calcium-binding mitochondrial carrier protein SCaMC-1 5 1.577 ± 0.083 
IPI00007320 TCF25  Transcription factor 25 3 1.782 ± 0.278 
IPI00020418 RRAS  Ras-related protein R-Ras 2 1.492 ± 0.189 
IPI00376215 PRKDC  Isoform 2 of DNA-dependent protein kinase catalytic subunit 2 1.433 ± 0.041 
IPI00000816 YWHAE  14-3-3 protein epsilon 23 1.476 ± 0.029 
IPI00216057 SORD  Sorbitol dehydrogenase 2 1.667 ± 0.345 
IPI00000874 PRDX1  Peroxiredoxin-1 42 1.5 ± 0.051 
IPI00026970 SUPT16H  FACT complex subunit SPT16 7 1.575 ± 0.114 
IPI00301323 DDX18  ATP-dependent RNA helicase DDX18 5 1.398 ± 0.071 
IPI00027252 PHB2  Prohibitin-2 26 1.55 ± 0.121 
IPI00646813 TROVE2  60 kDa SS-A/Ro ribonucleoprotein isoform 1 4 1.392 ± 0.059 
IPI00916229 MAT2A  S-adenosylmethionine synthase 4 1.539 ± 0.158 
IPI00020021 DEK  Protein DEK 9 1.436 ± 0.02 
  




No. Gene name Protein name Peptides 
Fold change# 
(±S.D.) 
IPI00006442 COIL  Coilin 3 1.479 ± 0.064 
IPI00017289 SNRNP27  U4/U6.U5 small nuclear ribonucleoprotein 27 kDa protein 2 1.396 ± 0.059 
IPI01013413 ACTR3  Actin-related protein 3 7 1.587 ± 0.341 
IPI00183508 TWF1  Twinfilin-1 2 1.616 ± 0.314 
IPI00984332 CD58  Isoform 2 of Lymphocyte function-associated antigen 3 2 1.614 ± 0.345 
IPI00939917 SMARCD2  Isoform 3 of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 2 1.466 ± 0.047 
IPI00644108 BUB3  Mitotic checkpoint protein BUB3 12 1.442 ± 0.053 
IPI00746062 PPP4R2  Isoform 2 of Serine/threonine-protein phosphatase 4 regulatory subunit 2 2 1.54 ± 0.117 
IPI00555593 PDLIM5  Enigma homolog (Fragment) 10 2.281 ± 1.367 
IPI00952607 CCT7  T-complex protein 1 subunit eta isoform d 10 1.454 ± 0.137 
IPI00298111 SNX6  Sorting nexin-6 isoform b 2 1.442 ± 0.046 
IPI01021277 DCTN2  Dynactin subunit 2 5 1.555 ± 0.297 
IPI00646917 NUDT21  Cleavage and polyadenylation specificity factor subunit 5 4 1.418 ± 0.052 
IPI00015897 CHORDC1  Cysteine and histidine-rich domain-containing protein 1 6 1.497 ± 0.11 
IPI00373882 RFC3  Replication factor C subunit 3 isoform 2 2 1.521 ± 0.226 
IPI00797421 SDAD1  Isoform 2 of Protein SDA1 homolog 2 1.443 ± 0.119 
IPI00941907 STRAP  Serine-threonine kinase receptor-associated protein 5 1.411 ± 0.12 
IPI00013930 STX6  Syntaxin-6 2 1.405 ± 0.059 
IPI00384967 ALDH1A3  Aldehyde dehydrogenase family 1 member A3 2 1.462 ± 0.217 
IPI00386803 LASP1  Isoform 2 of LIM and SH3 domain protein 1 8 1.464 ± 0.208 
IPI00465248 ENO1  Alpha-enolase 58 1.352 ± 0.038 
IPI00374657 VAPA  Isoform 2 of Vesicle-associated membrane protein-associated protein A 17 1.436 ± 0.088 
IPI00004968 PRPF19  Pre-mRNA-processing factor 19 6 1.418 ± 0.07 
IPI00644220 HTATSF1  HIV TAT specific factor 1 4 1.541 ± 0.189 
  




No. Gene name Protein name Peptides 
Fold change# 
(±S.D.) 
IPI00465028 TPI1;TPI1P1  Triosephosphate isomerase isoform 2 32 1.318 ± 0.008 
IPI00843876 TNPO1  Isoform 2 of Transportin-1 6 1.399 ± 0.123 
IPI00028883 NDUFB8  NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial 2 1.505 ± 0.329 
IPI00395627 CACYBP  Calcyclin-binding protein 20 1.443 ± 0.195 
IPI00003362 HSPA5  78 kDa glucose-regulated protein 110 1.35 ± 0.044 
IPI00069309 LRWD1  Leucine-rich repeat and WD repeat-containing protein 1 2 -1.39 ± 0.155 
IPI00718940 PRKRA  Isoform 2 of Interferon-inducible double stranded RNA-dependent protein kinase activator A 4 -1.549 ± 0.214 
IPI00093057 CPOX  Coproporphyrinogen-III oxidase, mitochondrial 35 -1.51 ± 0.281 
IPI00001734 PSAT1  Phosphoserine aminotransferase 4 -1.414 ± 0.096 
IPI00216492 HNRNPH3  Isoform 2 of Heterogeneous nuclear ribonucleoprotein H3 5 -1.48 ± 0.135 
IPI00916892 NUP35  Nucleoporin NUP53 2 -1.467 ± 0.136 
IPI00027107 TUFM  Elongation factor Tu, mitochondrial precursor 31 -1.468 ± 0.211 
IPI00967000 CHCHD6  Coiled coil helix cristae morphology protein 1 2 -1.474 ± 0.22 
IPI00396967 FHL2  Four and a half LIM domains protein 2 2 -1.394 ± 0.064 
IPI00607723 OGT  UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit 2 -1.375 ± 0.024 
IPI01014026 LAMTOR1 Ragulator complex protein LAMTOR1 3 -1.525 ± 0.224 
IPI00336094 HSD17B10  Isoform 2 of 3-hydroxyacyl-CoA dehydrogenase type-2 2 -1.553 ± 0.171 
IPI00177716 HMGA1 High mobility group protein HMG-I/HMG-Y 3 -1.368 ± 0.026 
IPI00030131 TMPO  Isoform Beta of Lamina-associated polypeptide 2, isoforms beta/gamma 37 -1.434 ± 0.094 
IPI01011752 DNAJB12 Isoform 2 of DnaJ homolog subfamily B member 12 4 -1.333 ± 0.026 
IPI00465256 AK3 GTP:AMP phosphotransferase, mitochondrial 4 -1.544 ± 0.193 
IPI01021818 PPHLN1 Periphilin-1 3 -1.354 ± 0.012 
IPI00554711 JUP Junction plakoglobin 7 -1.376 ± 0.064 
IPI00216659 RBM8A Isoform 2 of RNA-binding protein 8A 2 -1.461 ± 0.104 
  




No. Gene name Protein name Peptides 
Fold change# 
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IPI00007001 MRPL11 39S ribosomal protein L11, mitochondrial 5 -1.438 ± 0.056 
IPI00872762 SUCLG1 Succinyl-CoA ligase [GDP-forming] subunit alpha, mitochondrial 5 -1.479 ± 0.087 
IPI00293350 TSNAX Translin-associated protein X 3 -1.604 ± 0.347 
IPI00443909 CNPY2 Protein canopy homolog 2 6 -1.39 ± 0.053 
IPI00783250 TRIP12 E3 ubiquitin-protein ligase TRIP12 2 -1.542 ± 0.145 
IPI00789428 MCCC2 Isoform 2 of Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial 2 -1.515 ± 0.236 
IPI00101163 MTERFD1 mTERF domain-containing protein 1, mitochondrial 2 -1.417 ± 0.027 
IPI00297579 CBX3  Chromobox protein homolog 3 11 -1.373 ± 0.035 
IPI00641924 MRPS9  28S ribosomal protein S9, mitochondrial 5 -1.657 ± 0.466 
IPI00917908 PPIG Peptidyl-prolyl cis-trans isomerase G 2 -1.368 ± 0.057 
IPI00018098 PRPF38B Pre-mRNA-splicing factor 38B 2 -1.459 ± 0.109 
IPI00221106 SF3B2 Splicing factor 3B subunit 2 41 -1.379 ± 0.037 
IPI00218448 H2AFZ Histone H2A.Z 12 -1.49 ± 0.188 
IPI00827857 ABI1 Isoform 9 of Abl interactor 1 2 -1.418 ± 0.064 
IPI00011913 HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 8 -1.449 ± 0.127 
IPI00852584 RBM33 RNA-binding protein 33 2 -1.367 ± 0.075 
IPI00025176 SMNDC1  Survival of motor neuron-related-splicing factor 30 3 -1.5 ± 0.05 
IPI00744507 CSNK2A1 Casein kinase II subunit alpha 11 -1.371 ± 0.069 
IPI00013830 SNW1 SNW domain-containing protein 1 6 -1.475 ± 0.174 
IPI00025285 ATP6V1G1 V-type proton ATPase subunit G 1 3 -1.495 ± 0.1 
IPI00060107 CHCHD1 Coiled-coil-helix-coiled-coil-helix domain-containing protein 1 2 -1.819 ± 0.357 
IPI00328619 COQ6 Ubiquinone biosynthesis monooxygenase isoform b 2 -1.401 ± 0.074 
IPI00009943 TPT1 Tumor protein, translationally-controlled 1 6 -1.461 ± 0.036 
IPI00007729 NOL7  Nucleolar protein 7 6 -1.447 ± 0.046 
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IPI00163644 OSBPL8 Oxysterol-binding protein 3 -1.656 ± 0.247 
IPI00290460 EIF3G Eukaryotic translation initiation factor 3 subunit G 5 -1.469 ± 0.038 
IPI00807545 HNRNPK  Isoform 3 of Heterogeneous nuclear ribonucleoprotein K 27 -1.549 ± 0.153 
IPI00019380 NCBP1  Nuclear cap-binding protein subunit 1 2 -1.997 ± 0.816 
IPI00433048 CREB1 Cyclic AMP-responsive element-binding protein 1 2 -1.859 ± 0.639 
IPI01014074 PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 10 -1.4 ± 0.101 
IPI00304187 RBM28  RNA-binding protein 28 7 -1.532 ± 0.156 
IPI00006052 PFDN2  Prefoldin subunit 2 5 -1.475 ± 0.046 
IPI00044761 PUS7 Pseudouridylate synthase 7 homolog 2 -1.425 ± 0.094 
IPI00789551 MATR3 Matrin-3 28 -1.484 ± 0.149 
IPI00410360 NGDN Isoform 2 of Neuroguidin 3 -1.436 ± 0.103 
IPI00916489 COPS8  COP9 signalosome complex subunit 8 2 -1.467 ± 0.091 
IPI00026167 NHP2L1 NHP2-like protein 1 10 -1.487 ± 0.144 
IPI00019906 BSG Isoform 2 of Basigin 16 -1.612 ± 0.035 
IPI00924935 TFRC Transferrin receptor protein 1 5 -1.467 ± 0.12 
IPI00641640 LSR Lipolysis-stimulated lipoprotein receptor isoform 1 2 -1.742 ± 0.328 
IPI00942760 MRPS27 28S ribosomal protein S27, mitochondrial 5 -1.829 ± 0.284 
IPI00550689 RTCB tRNA-splicing ligase RtcB homolog 5 -1.54 ± 0.062 
IPI00024551 EMC7 ER membrane protein complex subunit 7 2 -1.541 ± 0.147 
IPI00855924 EIF5AL1 Eukaryotic translation initiation factor 5A-1-like 28 -1.488 ± 0.104 
IPI00024919 PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial 38 -1.571 ± 0.119 
IPI00030363 ACAT1  Acetyl-CoA acetyltransferase, mitochondrial 13 -1.675 ± 0.051 
IPI00945153 NDUFA6 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 2 -1.599 ± 0.033 
IPI00304493 SRFBP1 Serum response factor-binding protein 1 2 -1.505 ± 0.107 
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IPI00434623 MBD2 Methyl-CpG-binding domain protein 2 2 -1.445 ± 0.165 
IPI00304692 RBMX Heterogeneous nuclear ribonucleoprotein G 13 -1.528 ± 0.099 
IPI00012199 CCDC86 Coiled-coil domain-containing protein 86 9 -1.537 ± 0.114 
IPI00030702 IDH3A Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 7 -1.677 ± 0.061 
IPI00395527 MINA  Isoform 4 of MYC-induced nuclear antigen 6 -1.689 ± 0.072 
IPI00001541 TIMM9 Mitochondrial import inner membrane translocase subunit Tim9 2 -1.64 ± 0.217 
IPI00382733 LRRFIP1  Isoform 3 of Leucine-rich repeat flightless-interacting protein 1 7 -1.541 ± 0.125 
IPI00328170 MOGS  Mannosyl-oligosaccharide glucosidase 2 -1.57 ± 0.135 
IPI00303568 PTGES2  Prostaglandin E synthase 2 3 -1.474 ± 0.193 
IPI00334282 FAM3C  FAM3C Protein FAM3C 5 -1.694 ± 0.169 
IPI00477842 SRSF8 Serine/arginine-rich splicing factor 8 2 -1.507 ± 0.18 
IPI00219148 CSDA Isoform 3 of DNA-binding protein A 14 -1.538 ± 0.21 
IPI00000811 PSMB6 Proteasome subunit beta type-6 2 -1.745 ± 0.366 
IPI00010346 NLN Neurolysin, mitochondrial 3 -1.5 ± 0.226 
IPI00795482 STAT1 Signal transducer and activator of transcription 1 3 -1.535 ± 0.196 
IPI00893933 MSH2 DNA mismatch repair protein n 2 -1.517 ± 0.227 
IPI00902976 WRNIP1 ATPase WRNIP1 2 -1.73 ± 0.131 
IPI00926925 OGDH 2-oxoglutarate dehydrogenase, mitochondrial 2 -1.664 ± 0.29 
IPI00328987 Bystin Bystin 7 -1.669 ± 0.118 
IPI00658000 IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 7 -1.618 ± 0.166 
IPI00011253 RPS3 40S ribosomal protein S3 5 -1.735 ± 0.118 
IPI00022648 EIF5 Eukaryotic translation initiation factor 5 6 -1.789 ± 0.049 
IPI00305668 MRPS6 28S ribosomal protein S6, mitochondrial 2 -2.316 ± 0.701 
IPI01010055 ANXA11 Annexin A11 4 -1.572 ± 0.211 
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IPI00930241 EBNA1BP2 rRNA-processing protein EBP2 isoform 1 9 -1.781 ± 0.045 
IPI00945375 CUTA Acetylcholinesterase-associated protein 2 -1.7 ± 0.267 
IPI00945507 SUCLG2 Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial isoform 1 precursor 2 -1.561 ± 0.244 
IPI00397571 NSFL1C  Isoform 3 of NSFL1 cofactor p47 5 -1.67 ± 0.173 
IPI00106491 MRTO4 mRNA turnover protein 4 homolog 2 -1.755 ± 0.14 
IPI00642457 APRT  Adenine phosphoribosyltransferase isoform b 2 -1.786 ± 0.184 
IPI00793997 IPO8 Importin-8 isoform 2 2 -1.995 ± 0.404 
IPI00003327 ARL3 ADP-ribosylation factor-like protein 3 2 -1.67 ± 0.214 
IPI00307591 ZNF609  Zinc finger protein 609 2 -1.704 ± 0.181 
IPI00293078 DDX27 ATP-dependent RNA helicase DDX27 6 -1.99 ± 0.153 
IPI00966829 ALB Afamin 2 -1.94 ± 0.045 
IPI00029264 CYC1  Cytochrome c1, heme protein, mitochondrial 9 -1.964 ± 0.167 
IPI00922178 KIAA1598 Isoform 5 of Shootin-1 3 -1.767 ± 0.256 
IPI00971018 TARDBP  TAR DNA-binding protein 43 3 -1.837 ± 0.161 
IPI00375462 SREK1  Isoform 2 of Splicing regulatory glutamine/lysine-rich protein 1 7 -1.87 ± 0.151 
IPI01011396 IDH3G Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial isoform b precursor 3 -1.752 ± 0.217 
IPI01013183 COPE  Coatomer subunit epsilon 2 -1.989 ± 0.011 
IPI00902914 TM9SF2  Transmembrane 9 superfamily member 2 2 -1.64 ± 0.366 
IPI00242630 HEATR2 HEAT repeat-containing protein 2 3 -1.978 ± 0.266 
IPI00060627 CCDC124  Coiled-coil domain-containing protein 124 3 -1.803 ± 0.311 
IPI00027172 CLIP1 Isoform 2 of CAP-Gly domain-containing linker protein 1 4 -2.154 ± 0.131 
IPI00171798 MTA2  Metastasis-associated protein MTA2 2 -1.664 ± 0.403 
IPI00742943 NUP43 Nucleoporin Nup43 4 -2.153 ± 0.487 
IPI00748354 CHCHD4 Mitochondrial intermembrane space import and assembly protein 40 2 -2.248 ± 0.344 
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IPI00549248 NPM1 Nucleophosmin 29 -2.012 ± 0.165 
IPI00470870 TRIP6  Thyroid receptor-interacting protein 6 2 -2.111 ± 0.134 
IPI00449112 OGFR Opioid growth factor receptor 3 -2.117 ± 0.138 
IPI00026268 GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 6 -2.865 ± 1.104 
IPI00784224 ZFR Zinc finger RNA-binding protein 9 -2.139 ± 0.214 
IPI00647528 EXOSC2 Exosome complex component RRP4 4 -1.773 ± 0.525 
IPI00879460 SPTY2D1 Isoform 2 of Protein SPT2 homolog 2 -2.13 ± 0.352 
IPI00026230 HNRNPH2 Heterogeneous nuclear ribonucleoprotein H2 10 -2.319 ± 0.301 
IPI00217354 ARFGAP1  Isoform 2 of ADP-ribosylation factor GTPase-activating protein 1 3 -2.311 ± 0.144 
IPI00719622 RPS28  40S ribosomal protein S28 2 -2.068 ± 0.715 
IPI00031109 NDUFAF2  Mimitin, mitochondrial 3 -2.646 ± 0.285 
IPI00411706 ESD  S-formylglutathione hydrolase 2 -3.162 ± 0.209 
IPI00013774 HDAC1 Histone deacetylase 1 18 -2.059 ± 1.059 
IPI01010080 STRN4 Striatin-4 3 -2.555 ± 0.756 
IPI00031612 UTP23 rRNA-processing protein UTP23 homolog 2 -2.422 ± 0.961 
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Appendix III: Commonly altered proteins identified by iTRAQ and SWATH 
Accession 
No. Gene name Protein name 
Fold change# in 
iTRAQ(±S.D.) 





IPI00009276 PROCR Endothelial protein C receptor precursor 1.568 ± 0.207 2.088 ± 0.506 Y 
IPI00015897 CHORDC1 Cysteine and histidine-rich domain-containing protein 1 1.497 ± 0.11 1.531 ± 0.192 Y 
IPI00019906 BSG Isoform 2 of Basigin -1.612 ± 0.035 -1.57 ± 0.102 Y 
IPI00024320 RBM3 RNA-binding protein 3 1.822 ± 0.102 1.606 ± 0.245 Y 
IPI00182373 P4HA2 Prolyl 4-hydroxylase subunit alpha-2 1.723 ± 0.1 3.271 ± 1.7 Y 
IPI00289159 GLS Glutaminase kidney isoform, mitochondrial 2.117 ± 0.388 2.016 ± 0.665 Y 
IPI00418497 TIMM50 Isoform 2 of Mitochondrial import inner membrane translocase subunit TIM50 1.793 ± 0.157 -1.638 ± 0.117 N 
IPI00550689 RTCB tRNA-splicing ligase RtcB homolog -1.54 ± 0.062 -1.448 ± 0.157 Y 
IPI00641924 MRPS9  28S ribosomal protein S9, mitochondrial -1.657 ± 0.466 3.453 ± 0.428 N 
IPI00746438 RPL11 Isoform 2 of 60S ribosomal protein L11 1.951 ± 0.314 1.849 ± 0.337 Y 
IPI00759832 YWHAB Isoform Short of 14-3-3 protein beta/alpha 2.594 ± 0.316 -1.841 ± 0.432 N 
IPI00789428 MCCC2 Isoform 2 of Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial -1.515 ± 0.236 1.558 ± 0.122 N 
IPI00900380 MCTS1 Isoform 2 of Malignant T cell-amplified sequence 1 2.563 ± 0.284 1.618 ± 0.127 Y 
IPI00910593 CNN2 Calponin-2 2.005 ± 0.45 1.598 ± 0.192 Y 
IPI00924935 TFRC Transferrin receptor protein 1 -1.467 ± 0.12 -1.409 ± 0.111 Y 
IPI00945153 NDUFA6 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 -1.599 ± 0.033 4.472 ± 1.103 N 
IPI00966829 ALB Afamin -1.94 ± 0.045 -4.716 ± 3.516 Y 
IPI00967869 CAMK2D Calcium/calmodulin-dependent protein kinase type II subunit delta 1.651 ± 0.174 -1.674 ± 0.242 N 
IPI00980165 MANF Mesencephalic astrocyte-derived neurotrophic factor 1.54 ± 0.044 1.518 ± 0.161 Y 
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